Podcasts about daraprim

Deb (00:03.606)Within the next seven months, up to 1.5 million Americans could lose access to a medication that they’ve relied on for decades. Not because it’s dangerous, but because a pharmaceutical giant may have lobbied the FDA to eliminate their competition. And if you’re one of them, your doctor may already have told you about this issue and stopped prescribing it.This isn’t a conspiracy theory. This is documented in federal court filings. This is happening right now. And the company that stands to profit, well, they’re the same ones manufacturing the only product that might survive.Today on Let’s Talk Wellness Now, we’re exposing the desiccated thyroid extract crisis, the corporate manipulation behind it, and what you need to do right now to protect your health. Stay with me because I’m about to share what could save your access to the medication keeping you alive.Welcome back to Let’s Talk Wellness Now, the show where we uncover the root causes of chronic illness, expose regulatory capture in healthcare, and empower you with the tools to advocate for yourself. I’m Dr. Deb, naturopathic doctor, your medical detective, and today we’re diving into one of the most consequential and corrupt healthcare decisions affecting patients right now. If you or someone you love takes Armour thyroid, NP thyroid, or any desiccated thyroid extract,for hypothyroidism or if you’ve struggled to find a thyroid medication that actually works for your body, this episode is absolutely critical. And if you have celiac disease, gluten sensitivity or corn allergies, what I’m about to reveal will make your blood boil. Now grab your cup of coffee, don’t forget your notebook and settle in because what’s happening to this medication right now is a masterclass in how pharmaceutical companies use regular Deb (02:06.544)agencies to eliminate competition, control markets, and price gouge patients. And I have all the receipts. Deb (02:20.982)Let me start with what might surprise you. Desiccated thyroid extract, or DTE as we call it, is actually one of the most oldest thyroid medications in the world. And I mean old. From the 1890s through 1970, this was the standard treatment for hypothyroidism.Now let’s really dive into that. From the 1890s to the 1970s, this was standard hypothyroidism treatment.In 1965 alone, and this is documented in peer-reviewed literature published in the Journal of Clinical Endocrinology and Metabolism, approximately four out of every five prescriptions for thyroid hormone in the United States were of natural desiccated thyroid preparations.The Journal of Clinical Endocrinology and Metabolism is a very high-end journal. Now think about that. This wasn’t some fringe therapy. This was mainstream medicine. Armour Thyroid, the most recognizable brand name, has been manufactured since the early 1900s, well over a century ago.and this is cited again in NIH bookshelf. When the FDA was officially established in 1938, Arbor thyroid was already on the market. And this is important and I want you to understand why. Under the federal Food, Drug and Cosmetic Act, any drug that was already being marketed before 1938 was automatically grandfathered into the system. That means it didn’t have to Deb (04:08.112)go through the formal FDA approval process. And this again is cited under the Federal Food, Drug and Cosmetic Act, grandfathered drugs and exemptions. And this is crucial to understanding what happens next. By the 1970s, synthetic levothyroxine, brand name Synthroid and generics became the preferred treatment. Hmm, wonder why?It was easier to standardize, came into consistent doses, and worked well for most patients, and could be mass manufactured. By the 1980s, levothyroxine had largely replaced desiccated thyroid in clinical practice, according to the American Thyroid Association 2014 guidelines for the treatment of hypothyroidism. But here’s what matters. Some patients…a very significant minority of them, never felt right on levothyroxine alone. Despite their lab work looking normal, they still had fatigue, brain fog, weight gain, cold intolerance, and depression.These patients often found relief when they switched back to their desiccated thyroid, which contains both T4 and T3 hormones, the way human thyroid naturally produces them. And this is not anecdotal. This is documented in randomized double-blind crossover studies published in Endocrine Practice.For decades, that was fine. Their doctors prescribed it, insurance sometimes covered it, patients were getting better, and the system worked really well. Until August 6th of 2025, just a short time ago, everything changed. On that date, the FDA sent letters to manufacturers, importers, and distributors of desiccated thyroid extract products stating that these medications would need an approval. Deb (06:04.654)a biologics licensed application, a BLA, to remain legally on the market. And this is cited in the FDA’s official statement, FDA’s actions to address unapproved thyroid medications. understand it says unapproved thyroid medications. However, desiccated thyroid, specifically Armour, has been approved since 1938. And this was dated August 6th through 7th, 2025.This wasn’t a guideline. This wasn’t a suggestion. It was an endorsement of action. And the timeline they gave them? Well, just 12 months to transition patients to another medication before enforcement action could begin.This was also cited by an FDA notice to the industry, animal derived thyroid products notice to industry, August 6th, 2025. Now do the math, that means August 2026, seven months from now, 1.5 million Americans currently taking this medication. And this number comes from the FDA official statement, citing that it’s an estimation of 1.5 million patients receiving prescriptions for these medications.could potentially lose their thyroid access. Now, here’s where it gets interesting. The FDA didn’t wake up in August of 2025 and decide to regulate desiccated thyroid after a century. This decision has a much longer backstory. And understanding that backstory is critical to understanding what’s really happening in this industry.The shift started in 2022. Back in September of 2022, over three years ago, an FDA branch chief sent a letter to the National Associations of Boards of Pharmacy noting that the agency had decided to designate DTE as a biological product, which would affect its eligibility for compounding. Deb (08:13.972)This also is cited in an FDA letter to the National Association of Boards of Pharmacy September 2022.Then two months later, in November of 2022, the FDA’s Office of Compounding Quality and Compliance sent a softer letter acknowledging that many Americans take medication to treat hypothyroidism and some choose to take DTE products. The letter stated that the FDA would focus enforcement on cases that pose the greatest public health risks, such as serious adverse offense or serious product quality or adulteration.also is cited by an FDA letter from Francis G. Bromel, the director, Office of Compounding Quality and Compliance, November of 2022. Now, let me just think about this for a second. If this drug has been on the market since the 1800s, been FDA approved since 1938, would we not have seen a health crisis long before 2022?I honestly don’t know of any other drug that’s been around this long that’s used by this many people. Now granted, I haven’t done the research on it either, which I can do for you guys, but I’m just thinking if a drug is on the market today and it causes harm, it doesn’t make it three years, five years before you see lawsuits everywhere. Why are there no lawsuits on this drug? Why are there no major reactions that people are seen having?Hmm, just thought. But here’s the pattern. The FDA was already laying the groundwork back in 2022, testing the waters, signaling where this was headed. The August 2025 action. Then this came down. Deb (10:09.806)August 6, 2025, the FDA announced its position publicly and sent formal letters to all DTE manufacturers, importers, and distributors. This was cited by the FDA Enforcement Action August 6, 2025, letters to manufacturers, importers, distributions of DTE products. The agency stated several concerns. First, DTE products have experienced quality and dosing issues.The FDA cited, and I’m quoting directly from their statement, over 500 adverse events reported associated with DTE products from 1968 to 2025. From 1968 to 2025, we had 500 adverse reactions? What is that math equate to?A couple a year? Come on guys, this is insane! With a substantial increase, you, between 2019 and 2020 that the agency suggested was related to voluntary recalls of sub-potent or super-potent products.This was cited in the FDA statement, over 500 adverse events reported associated with ADT products from 1968 through 2025.Second, the agency expressed concern about batch inconsistency. According to the FDA’s official statements, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Okay, this was cited in the FDA statement, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Thirdly, and I want to actually let’s back up. I want you to remember I said that Deb (12:11.216)because further down in this podcast, we’re going to talk about this. This is an important point to remember. Thirdly, the agency raised concerns about potential impurities from animal source material, including potential for viral contamination due to the animal source and supraphysiological levels of T3.the FDA statement on impurities, viral contamination and super physiological T3 levels. Now I will tell you, I’ve been prescribing armarithograde for 20 years. I’ve rarely seen a super physiological dose given of T3 in lab results, unless the patient takes their medication like four or five hours before you do the blood test, then you’ll see a false rise because you’re actually seeing the medication. You’re not seeing people walking aroundsuperphysiological T3 levels. Nobody would like that feeling. So anyway, I digress. Now let me pause here because this is where I need to give you some context that the FDA hasn’t quite emphasized yet. Of course, we have another connection and it is the China connection.So the FDA’s concerns about contaminated drugs and quality issues don’t exist in a vacuum. In 2024, the U.S. over 828,000 metric tons of pharmaceuticals, seven times the level from 2000. And here’s the kicker. China and India supply the majority of active pharmaceutical ingredients. APIs for U.S. generics accounting for 70 to 80 % of the total genericdrug supply. According to Reuters industry report in 2024, they state that China supplies 82 % of the APIs for critical drugs. Deb (14:08.204)Got to question that, right? Why are we giving all of our drug formulas to China and allowing them to import them into our country? In fact, roughly 20 % of the critical drugs have APIs exclusively sourced from China. And China controls 80 to 90 % of the global production for antibiotics and other key compounds. This was also cited by Reuters industry data thatcontrols 80 to 90 percent of the global production for antibiotics and other key compounds. Now just think about this. They control 80 to 90 percent of our medication. They control 20 percent of our critical drugs and we just put what kind of tariff on them? Hmm.In 2025 alone, the FDA issued multiple warning letters to foreign manufacturers for contamination issues and failure to follow good manufacturing practices. This is also cited by the FDA warning letters 2024 through 2025 and multiple citations to foreign manufacturing facilities. This is a systematic problem affecting the entire US drug supply, not just desiccated thyroid.So when the FDA suddenly became concerned about DTE quality and contamination, part of that concern was legitimate. But this is crucial. The same inconsistencies and contamination issues exist across the entire generic drug supply. And the FDA has not taken the same enforcement action against them. Let that sink in.They have not taken the same enforcement action against the other drug companies. So what’s behind all of this? Where is this all coming from? Hmm. Let’s address something directly, because you deserve to know it. And I’m going to cite my sources precisely so that when the medical boards have something to say about this, and they might, I have a documentation for every single word that I am about to speak. Deb (16:24.878)According to the court documents filed in October 2025, in the case ofa urine, a urine. I’m going to say that wrong. Pharmaceuticals versus Dr. George Tidmarsh from ABBV, the multinational pharmaceutical company that manufactures armor thyroid, reportedly petitioned the FDA in 2024, asking the agency to reclassify DTE as a biologic and to prohibit other manufacturers from selling unlicensed DTE products unless they havehad an investigational new drug application, we call this an IND, and a clinical development program aimed at eventual approval. This is cited in the court filing a Urena pharmaceuticals lawsuit versus Dr. George Tidmarsh, October 2025, reported by Fierce Pharma. Now let me explain why this matters and why this is one of the most brazen examples of regulatory capture I’ve ever seen in my career.AbbeVee is one of the world’s largest pharmaceutical companies. In 2024, they reported over $54 billion in revenue. Drop the mic on that one.They have the resources, the regulatory expertise, the legal teams, and the financial capacity to navigate a biologics license application process that costs between $500 million and $1 billion. Let that sink in. Deb (18:07.882)A drug that’s been on the market since the 1800s that was grandfathered in 1938 that’s making plenty of money right now. They’re going to spend 500 million to $1 billion to get a biologics license application. Why would they do that? Well, we’re about to find out. Most otherDTE manufacturers, smaller companies like Acela Pharmaceuticals, which makes NP-thyroid, and RLC Labs, which made WP-thyroid, do not have those same resources. And this is cited in Pharma Voice in 2025. Why a treatment older than the FDA is getting new regulatory scrutiny. So when you petition the FDA to reclassify a drug in a way that requires this type of expensivetime-consuming biological approval, you’re not just asking for safety. You’re asking to eliminate your competitors from the marketplace. Now, I want to be very precise here. These allegations are documented in federal court filings, and it hasn’t been approved in court. It’s also been reported by multiple industry sources, including Fierce Pharma. But I’m telling you,what has been reported in legal proceedings, not stating it as an absolute fact because you deserve to know the difference and because I have to protect my license. Now, what do we know for certain?AbbeVee is working on a biologics license application for Armour thyroid through clinical trials called Avantia. This is cited by the AbbeVee corporate statement 2025 Avantia clinical trial for Armour thyroid. A cell of pharmaceuticals has been pursuing BLA approval for NP thyroid for seven years since 2017 and it completed its phase two trials successfully in 2025. They’re now moving Deb (20:15.448)into Phase 3 trials. This is also cited by the Acela Pharmaceuticals CEO statement 2025 seven-year pursuit for BLA approval completed Phase 2 trials moving to Phase 3.RLC Labs, which manufactured WP thyroid, has made no public announcement about pursuing BLA approval and really probably don’t have a plan to do this since they’ve been off the market for some time now. About five years, I think maybe a little longer. Here’s the market manipulation.If only ABBV is successful and obtains a BLA approval for Armour thyroid, that company would effectively have a monopoly on the DDT market. And in pharmaceutical markets, monopolies historically lead to price increases.We’ve seen this pattern over and over again when turning pharmaceuticals acquired Daraprim and raised their price from $13.50 to $750 per tablet overnight. When Myelin raised EpiPen increased prices by 400 % when insulin manufacturers colluded to raise prices in lockstep. This is the playbook.use regulatory barriers to eliminate your competition and then exploit pricing power. For a drug that’s been on the market since the 1800s, guess corporate greed is everywhere. They’re not making enough money on this product already and they’re taking advantage of the rules that they can manipulate their competition by. And here’s what really makes me furious. The American Thyroid Association, the professional organization Deb (22:06.672)representing endocrinologists sent letters to the FDA commissioner on October 8th of 2025 and September 18th of 2025.advocating for continued patient access to DTEs. This is cited in the American Thyroid Association statement and letter to the FDA commissioner dated October 8th, 2025 and September 18th, 2025. The American Association of Clinical Endocrinologists issued a statement on September 9th of 2025 supporting equitable access and personalized medicine for DTE. This was also cited in the American AssociationAssociation of Clinical Endocrinologists, AACE, statement dated September 9th, 2025. Even the medical establishment, which has historically favored levothyroxine, is saying, wait, this is going too far. Patients need access to this medication. But the FDA is moving forward anyway. Why? Well, where does it always lead us? Follow the money trail.Okay, so I need to explain what a biologics license application actually is because this is where the rubber meets the road for what’s going to happen to pricing and availability. What is a BLA?A BLA is a biologics license application. It’s a formal request submitted to the FDA to market a biologic product in the United States. A biologic is defined under the Public Health Service Act section 351 as a product derived from or made using living material, in this case, animal thyroid glands. And this is cited in the FDA definition for biologic products. So they’re putting armor thyroid right Deb (23:57.377)right up with stem cells and exosomes. Think about that. Stem cells and exosomes cost thousands of dollars per application because of how they have to be harvested, stored, freezed, all of that. But we’re talking about a thyroid gland. Good Lord, people.Unlike regular drug applications for synthetic medications which follow a simpler pathway, the BLA process is designed for complex biological products like monoclonal antibodies, vaccines, and gene therapy products. It’s a much more expensive, much more time-consuming process. The BLA processis what manufacturers have to do. And we’re going to talk about that. So according to Reprocell and Forge Biologics analysis of the FDA’s BLA process, here’s what companies need to submit. First, they need to complete a clinical trial data, phase one, two, and three trials, proving safety and efficacy for desiccated thyroid. Haven’t we done that since it’s been on the market since the 1800s? Just saying.This means they have to conduct large randomized controlled trials comparing it to levothyroxine, measuring safety outcomes, efficacy outcomes, and quality of life metrics. Second,Chemistry, Manufacturing and Controls, CMC’s data. Detailed information about how the product is manufactured, quality control measures, stability testing and specifications that must be met for every batch. Third, preclinical and animal safety data. Fourth, labeling and product information. Now, I think we have labeling and product information. Deb (25:53.717)since the 1800s? But just saying. Fifth, they need Pharma Covigilance Plan, a detailed plan for monitoring safety after the product is on the market. Haven’t they had to do that since the 1800s? And they have to have a timeline. And this is the critical part. The FDA’s standard review time for a BLA is 10 months.That’s after the application is deemed complete and accepted for filing. So this is cited by the FDA standard review timeline, BLA submission, and FDA review.Now, before you even get to filing, you need to conduct the clinical trials and compile all the data that’s typically several years of work. How are you going to prove safety and effectiveness in a large clinical trial long term? What do they consider? What do they deem long term? Three months, six months, a year, two years. These companies had 10 months.Well, maybe 12. They did it a year in advance. But unless you knew this was coming, how are you going to put together a trial, enroll the people, have all the trial components set up and ready to go in less than 12 months unless you knew it was coming beforehand? Even ifhad started all their clinical trials in 2024, completing them, compiling the data, and getting a complete application ready for submission, this would likely take you through mid-2026, then add another 10 months for FDA review. We’re looking at 2027 at the earliest for most of these companies to receive a BLA application. Deb (27:54.319)But the FDA gave the manufacturers until August of 2026. That’s approximately 19 months from when the August 2025 letters were sent. Most companies cannot reasonably complete the BLA approval in that timeframe. And when I’m talking about the 19 months, I’m talking about the information they would have had earlier. Now the cost.This gets me even more frustrated. Why are we spending this kind of money? The BLL process is extraordinarily expensive. The current FDA user fee for a BLA submission is approximately $483,560 just for the filing fee. And this is cited at the FDA user fees prescription drug user fee rates for 2025.The full cost of conducting clinical trials, CMC studies, and all the supporting documentation typically ranges from $500 million to over $1 billion, depending on the scope of the trials and the complexity. And this is cited in JAMA’s network, Open2023. A cell of pharmaceuticals has been pursuing the BLA approval since 2017. That’s eight years. And it’s just now.moving into phase three trials with a planned enrollment of approximately 300 patients. This is cited by the Acela Pharmacies CEO statement of 2025. Now that’s unusual. That’s typical for this process. This is not unusual. This is typical for this process to take seven, 10 years to get approval for this. So if Abby’s the one that requested this,Abby V. And Acela started this in 2017. Was Abby V threatened by Acela that Acela might get this approval and it would be quietly done without anybody seeing it? And maybe Abby V would be left out of the market after a century? Who knows? It’s possible. Deb (30:13.112)But for smaller manufacturers without billions in revenue, this cost is completely prohibitive. And this is why this matters. When you push an old established medication through an extraordinary, expensive approval process with a compromised timeline, one of three things happen. First, only the largest companies can afford it, creating a monopoly. And when that happens, the company that holds the only approved product can set pricing withminimal competitive pressures. Two, smaller manufacturers can’t afford it and their products disappear and the market shrinks and access decreases. Three, we see a combination of both and who pays the price? Literally, patients do. Now here’s whereThere’s something I want you to really think about because this is where the regulatory argument falls apart when you look at it carefully. The FDA’s concern about DTE is that, and I’m quoting their official statement, tablets from the same manufacturing batches may not always provide the same thyroid hormone levels. This is from their FDA statement.And that’s a legitimate quality concern, right? It is. Thyroid medications have a narrow therapeutic window like any other hormone, meaning the difference between an effective dose and the dose that causes problems can be quite small. But here’s what the FDA doesn’t emphasize. Generic drugs have the exact same dosing inconsistency issue, and it’s considered acceptable and has been since we allowed generics on the market.So how does a generic drug dose work anyway? Well, for generic drugs to be approved as bioequivalent to a brand name medication, the FDA requires that the generic drugs bioavailability fall within 80 to 125 % of the brand name product. Isn’t that a dose inconsistency? Deb (32:22.894)from the brand name medication? 800 or sorry, 80 to 125%. According to the pharmacy times analysis of the FDA’s bioequivalent standards, the 80 to 125 % bioequivalence rule means that a generic drug can have 20 to 45 % variability compared to the original brand product.Now, most generics are much closer than that. The FDA study data shows that the mean difference for an AUC value between generic and reference products is about three and a half percent in the two year post-Waxman hatch period, and 80 % of the generics fall within a five percent range. But the FDA’s regulations allow for that much higher variability. And this is cited in an FDA study data mean difference for AUC.Now, let me put this in plain language. A patient could take a generic levothyroxine tablet where one batch provides, say, 75 micrograms of an active thyroid hormone. And the next batch from a different manufacturer, a different generic manufacturer, could provide up to 93.75 micrograms, 125 % of that 75. That’s an 18 microgram difference.in the same prescribed dose. Now, this is considered acceptable and patients tolerate it and this system works.Yet the FDA’s argument against DTE is that batch-to-batch inconsistency is unacceptable and requires this expensive biologic approval? That’s a double standard. So why is batch inconsistency acceptable for generic levothyroxine, but supposedly unacceptable for desiccated thyroid? I’ll give you the regulatory answer. Deb (34:29.366)because DDT is a biological product derived from an animal tissue and the FDA considers biological products to require more rigorous control. That’s the regulatory answer, but I’ll give you the real answer.because there’s no billion dollar pharmaceutical company with a patent pending on generic levothyroxine who petitioned the FDA to regulate their competitors more strictly. The inconsistency argument is legitimate, but it’s selectively applied. And that matters when you’re trying to understand whether this is really about patient safety or whether it’s about market control.Now I want to talk about something that hasn’t gotten nearly enough attention in this discussion and it’s something that makes me absolutely furious. What is Armour Thyroid? According to the official prescribing information published by AbbeV and available through rxabbev.com and the FDA’s daily med database, Armour Thyroid contains the following inactive ingredients. Calcium steroid,dextrose derived from corn, mycocrystalline cellulose,sodium starch glycolate and a opadri white coating. Now let’s talk about dextrose. Dextrose is a sugar derived from corn and while manufacturers claim that the corn derived dextrose in armor thyroid is gluten free, here’s the problem. Cross contamination during corn processing can introduce gluten proteins especially if the corn is processed in facilities that also handle Deb (36:18.808)wheat, barley, or rye. Corn sensitivity is extremely common in patients with celiac disease and non-celiac gluten sensitivity, and studies show that up to 50 % of the celiac patients react to corn proteins due to molecular mimicry, and the corn proteins look similar enough to gluten that the immune system attacks them. And this is cited by RestartMD.com.And here’s what’s documented in peer-reviewed medical literature in a 2023 case report published in Case Reports in Endocrinology. These researchers documented five patients with gluten intolerance or celiac who were taking natural desiccated thyroid. Three of those patients also reported lactose intolerance. Now these patients had to switch from DTE to liquid levothyroxine formulations to avoid the inactiveSo here’s my question. If AbbeV becomes the only manufacturer with an approved DTE product and their formulations contain corn-derived dextrose that triggers reactions in celiac patients, what are those patients supposed to do? They can’t take armor because of the corn. They can’t take compounded DTE because the FDA is banning compounding of these biologics. They can’t take NPKsor WP thyroid because those companies may not survive the BLA process. So they’re left with a synthetic version of levothyroxine which may not work for them.Now the NP thyroid and WP thyroid difference. Now here’s what’s interesting according to drugs.com comparison of inactive ingredients and P thyroid and P thyroid has calcium steroid dextrose also derived from corn, mineral oil, multi-crystalline cellulose. Deb (38:19.31)cross carmelicin sodium and a opadri to white. So NP thyroid also has corn-derived dextrose. WP thyroid on the other hand was specifically formulated to be hypoallergenic according to ROC labs, but it’s no longer available and its ingredients were inulin from chicory root and medium chain triglycerides. No corn, no gluten, no common allergies. So todayWe do not have a glandular thyroid, a DTE, that is not potentially contaminated with gluten. Yet, patients with autoimmune thyroid disease are supposed to avoid gluten.Now, some of these people can handle a DTE and many cannot, so that argument could be a mute point. But at the end of the day, the one product that we had that was designated for patients with multiple chemical sensitivities, celiac disease and coron allergies, has been off the market for a long time already.We have a monopoly problem. So if ABBV becomes the only approved manufacturer, patients with these celiac diseases and corn allergies will either be forced to take a medicine that makes them sick and triggers their immune reaction or switch to a synthetic that doesn’t adequately treat their hypothyroidism or choose to go without treatment. This is not hypothetical. This is real patients with real medical needs who are about to lose accessto the only formulation that works for their body. And the FDA’s response is silence. Deb (40:07.69)Now I want to highlight something that hasn’t gotten nearly enough attention in this discussion. Compounding pharmacies. What is a compounding pharmacy? Compounded medications are custom made by licensed pharmacists to meet a patient’s specific needs. Maybe you need a different strength that was commercially available, but you have an allergy to a filler or a dye in the commercial product. Maybe you need a liquid formulation or instead of a tablet or you need a capsule. That’s when compoundingin. And the FDA’s, this is the FDA’s definition of compounding. And for decades, compounding pharmacies have been making desiccated thyroid extract for patients who needed customization. Some patients couldn’t take the commercial products because of the dyes and the fillers, and some needed strengths that were not available. And these compounding pharmacies filled the gap.But reclassification changes everything. When the FDA reclassified DTE as a biologic in 2022 and reinforced that decision in August of 2025, explicitly stated, and I’m quoting directly from the FDA’s official statement, these unapproved animal-derived thyroid medications are not eligible for compounding because these products are regulated as biologic products under the Public Health Service Act.How can that be? These products have been approved since 1938 and the Biologics Act didn’t go into effect or doesn’t go into effect until August of 2026.So how in 2022 were they able to say that the compounding pharmacies could not make these products? Anyway, what this means is after August 2026, compounding pharmacies will no longer be permitted to compound a desiccated thyroid extract, even for patients with specific medical needs. Now, compounding pharmacies can still compound T4 and T3 separately, synthetic versions of levothyroxine and liothyronine, according to Deb (42:12.728)healing dose compounding pharmacy. These pharmacists can create custom ratios of these two synthetic hormones to approximate what a patient was receiving from a DTE. But that’s not the same thing. Some patients respond better to the whole DTE preparation than to a compounded synthetic combination. And for patients with specific allergies to standard fillers like your celiac patients that I just talked about, losing the ability to get a compounded DTE alternative isreal hardship. This is going to be a ripple effect. For a subset of patients, maybe 5 to 10 percent of those on DTE compounding was their lifeline and it was their way to get a medication formulation that worked for their unique body. When compounding goes away, these patients lose that option as well and for some it will be a significant problem. Now let’s talk about what this likely means for your wallet.The current pricing right now, according to SingleCare and GoodRx, Armour Thyroid costs approximately $150 to $157 for a 90-day supply of 60-milligram tablets, about $1.67 per tablet. With discount cards, some patients can get it down to $101 to $152 for a 90-day supply.Generic levon thyroxine costs about $70 for a 90 day supply, less than half that price. And p-thyroid costs approximately $133 for a 90 day supply of 60 milligrams with a discount card about $83 to $101.What happens after we get BLA approval? Well, here’s the pharmaceuticals pricing model. When a company spends 500 million to $1 billion to bring a product to market, including conducting massive clinical trials, the cost tens of millions of dollars they recoup in that investment through pricing power. And this is cited in the pharmaceutical pricing models. If ABBIEV is the only company with an approved BLA of DTE, Deb (44:18.248)They have pricing power. They don’t have competitors. They can set their price, whatever they want. And historically, when drugs transition from grandfather status, which is basically unregulated to formal formally approved status, prices often increase significantly, not always, but often. And typically they have to get re-approval for insurance. SoTouring Pharmaceuticals acquired DARPM and raised the price again from $1,350 to $750 overnight, a 5,000 % increase. This is the playbook.Let’s talk about insurance coverage. This is the other consideration. Insurance companies sometimes have different coverage policies for approved versions versus unapproved drugs. And right now, many insurance plans cover armor thyroid or NP thyroid, even though they’re technically unapproved because they’ve been on the market for decades and patients are on them. Once a drug becomes formally approved, insurance companies may have new contractual relationships, prior authorization requirements, or preferred drugs.list that could affect your coverage. If 1.5 million people have to get a prior auth for their insurance to cover this new medication, this is going to drive the doctor’s offices crazy. We do not have the staff to man this. We do not have the manpower. We do not have the time. This is going to interrupt people’s ability to get their medications. This is going to create chaos within the system. And some patients might see better coverage, but manymost likely are going to see worse coverage and some might find themselves in a situation where they need to try to get the drug approved first or get an approval for something else like levothyroxine and they’re going to have to document that it didn’t work and the documentation that they had from 20 years ago is probably not going to be enough because it’s not documented anywhere. It’s lost in the system after 10 years. So for patients the practical takeaway is expect Deb (46:25.774)a price increase. I would say possible, but I don’t think that’s true. think you’re going to see a price increase if they get approved. Expect possible insurance complexities, budget accordingly, talk to your insurance company now about what your coverage is going to look like in 2027 if they even know. And if you want my honest assessment of what is likely to happen,I’ll give you a scenario, 30 % likelihood. The FDA enforces the August 26 deadline and DTE products not approved by then are pulled from the market. Patients will have 30 to 90 days to transition to other medications. Some patients suffer significant symptom relapse. Compounding for DTE becomes illegal and this disruptiveness of the system creates a real hardship. Scenario two.which is 50 % likely. This is actually what the FDA commissioner, Marty McCreary suggested on August 13th of 2025 when he posted on social media. The FDA is committed to pursuing the first ever approval of desiccated thyroid access pending results of the ongoing clinical trials. In the meantime, we’ll ensure access for all Americans. Hopefully that continues. What this likely means is the FDA uses enforcement discretion to allow continuedsales while approvals are being pursued and the deadline gets extended. Maybe patients get access for another two to three years while companies work on a BLA approval. This would be the least disruptive scenario, but it’s also legally uncertain because the enforcement letters have been formally rescinded. And scenario three, which is 20 % likelihood, one or two companies get BLA approval. Those products stay on the market at higher product prices and companies, products, other companiescompanies, products are pulled, the market shrinks, availability is limited, prices are higher, but patients can still get something. This is likely if a seller successfully completes phase three trials for NP-thyroid. And my assessment is based on the regulatory language and the enforcement letters that have not been rescinded yet, that the pattern of FDA enforcement, I believe scenario two enforcement discretion with an extended time frame is most likely what we’re going to see. Deb (48:49.488)doesn’t mean patients should sit back and do nothing. It means you should be prepared for change while advocating for access. If you want to keep Arm or Thigh Right on the market, 1.5 million people need to start talking about this publicly and flooding our Congress people, Bobby Kennedy, the FDA, with what you want to see happen. We have the ability to shape this and to change this with our voice. But if we sit back on our laurels and we do absolutelynothing. What is going to happen is what the FDA wants to have happen and ABV wants to have happen because they’re going to simply think people don’t give a shit. And if the American people are going to be lazy and not want to step forward and actually start using their voice for some good and instead of just going to social media and bitching and hoping something is going to happen, well, then we’re going to get what we deserve. But if you start taking someaction and you start advocating for the things that you want. Contacting your representatives, contacting your U.S. tell them the FDA has done this. Many of them may not know this, may not be on their radar. Tell them what you want. Start going after this. Start writing to the FDA Commissioner’s Office. They have a website. They have a Commissioner’s Office at fda.hhs.gov. Be responsible.respectful, but be firm. Explain your scenario. How long you’ve been on DTE. Why levothyroxine doesn’t work. What symptoms you experience when not adequately treated. How this decision will affect your quality of life and your pocketbook. Let’s do something proactive. So let’s consider this. Moving forward, work with your provider who understands the regulatory landscape around DTE. You can discuss the evidence for and against combination therapy.You can monitor for thyroid function with free T3 and free T4 testing, not just TSH. If you’re willing to try individualized approaches, you can do that. If you need help finding a functional medicine provider who understands this issue, come to serenityhealthcarecenter.com or explorethevanari.com. It’s a self-directed functional medicine support group. And right now what is happening is going to shape how history Deb (51:19.024)is made with not just armor thyroid, but many drugs to come. And it is important for you to take action. So I want to thank you for joining me today on Let’s Talk Wellness Now. This episode is about far more than thyroid medication. It’s about your right to personalized medical treatment. It’s about your regulatory capture and corporate influence. And it’s about what happens when billion dollar companies shape healthcare policy in ways that reduce patient choice and increase their profits.this episode resonates with you or you know somebody who’s going to be affected by desiccated thyroid, please share it. Post it on social media, send it to your doctor, email it to your representatives, tag AbbeVee, tag FDA. Make noise because the only way we stop this is if we make it too politically costly for them to continue. Your voice truly matters. Your health truly matters and you deserve access to treatments that work best for your unique body.If you’re ready to explore comprehensive personalized health care that puts you in control, visit us at SerenityHealthCareCenter.com. Learn more about functional medicine approaches to thyroid and beyond and explore my new platform, Venari.com, which is a self-directed functional medicine tool. Thank you for joining me today. Until next time, I’m Dr. Deb reminding you, your health is your responsibility, your choice, and your right. Be well, stay informed, fight back.and I’ll see you in the next episode. And if you’re looking for a full citation list of this episode, you can head over to letstalkwellnessnow.com and I will post all the citations for you so you have them in your arsenal as well. Thank you again.The post Episode 259 – The Desiccated Thyroid Crisis: FDA's Unseen Impact & Corporate Manipulation first appeared on Let's Talk Wellness Now.

Why You Should Listen:  In this episode, you will learn the role of Toxoplasmosis in chronic illness and approaches for addressing it. About My Guest: My guest for this episode is Dr. Eboni Cornish.   Eboni Cornish, MD, a highly regarded  physician, provides integrative medicine services to a diverse global patient community.  Currently serving as the Functional Medicine Director of the Amen Clinic East Coast Division, she specializes in autoimmune diseases, Lyme disease, environmental toxicity, gut imbalances, neurology and various other chronic conditions.  Employing a holistic approach, Dr. Cornish identifies the root causes of health issues within the body's biological systems, offering comprehensive treatment to adults and children. Her treatment philosophy is integrative and evidence-based.  Within Amen Clinics, Dr. Cornish has been instrumental in developing the Neuroinflammatory Intensive program—a two-week inpatient initiative addressing neurological complications arising from chronic infectious diseases, Lyme disease, mold illness, and other chronic inflammatory conditions including SPECT imaging.  Dr. Cornish's educational journey includes earning honors at Brown University for her undergraduate studies and obtaining her medical degree from Brown University Medical School. She further refined her skills through a family medicine residency at Georgetown University.  As a Howard Hughes Medical Fellow, Dr. Cornish conducted translational research at the National Human Genome Research Institute NIH, working under Francis Collins, MD, PhD.   She currently serves as the Treasurer of the board for the International Lyme and Associated Diseases Society and a fellow of the Institute of Functional Medicine.  Key Takeaways: What symptoms present in those with Toxoplasmosis? What conditions might Toxoplasma contribute to? How prevalent is Toxoplasma? How do people acquire Toxoplasma? What role do cats play in the transmission of Toxoplasma? Can Toxoplasma be transmitted by ticks? What are the best methods for testing for Toxoplasma? What is observed in these patients using SPECT scans? Does mold exposure potentially make Toxoplasma worse? Can Toxoplasma be a trigger for mast cells? How important is immune modulation as part of a treatment protocol? What pharmaceutical and natural options have been most helpful for treating those with Toxoplasma? Is there a place for homeopathy or frequency medicine? What is the connection between Toxoplasma and calcification? How important is limbic system retraining in these patients? Connect With My Guest:  http://AmenClinics.com Interview Date: February 23, 2024 Transcript: To review a transcript of this show, visit https://BetterHealthGuy.com/Episode197. Additional Information: To learn more, visit https://BetterHealthGuy.com. Disclaimer:  The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority. 

La industria farmacéutica desempeña un papel crucial en la sociedad al proporcionar medicamentos y tratamientos que mejoran y salvan vidas. Sin embargo, como en cualquier industria, también ha sido escenario de casos de fraude, estafas y mala praxis. Estos incidentes no solo erosionan la confianza del público en la industria, sino que también plantean cuestionamientos éticos sobre la priorización de las ganancias por encima de la salud y el bienestar de los pacientes. En este artículo, exploraremos algunos ejemplos notorios de fraudes, estafas y mala praxis en la industria farmacéutica, así como las implicaciones y las medidas tomadas para abordar estos problemas. Casos Emblemáticos de Fraude y Estafas Caso Turing Pharmaceuticals y el aumento de precios de Daraprim: En 2015, Turing Pharmaceuticals, dirigida por Martin Shkreli, adquirió los derechos del medicamento Daraprim, utilizado en el tratamiento de infecciones parasitarias. La compañía aumentó drásticamente el precio del medicamento en un 5,000%, lo que generó indignación pública y puso de relieve las prácticas de fijación de precios abusivas en la industria. Caso Insys Therapeutics y el opioidi OxyContin: Insys Therapeutics promovió de manera agresiva su fentanilo de acción rápida, Subsys, para el tratamiento del dolor, incluso cuando no estaba indicado. La compañía se enfrentó a acusaciones de sobornar a médicos para recetar el medicamento y participar en tácticas de marketing engañosas, lo que contribuyó a la crisis de opioides en Estados Unidos. Caso GlaxoSmithKline y el escándalo del Paxil: La compañía farmacéutica GlaxoSmithKline fue acusada de ocultar datos sobre la seguridad y eficacia del antidepresivo Paxil en pacientes jóvenes. También se reveló que GSK había sobornado a médicos y manipulado la información en beneficio propio. Casos de Mala Praxis y Fallos en la Investigación Retiro de medicamentos después de la aprobación: En ocasiones, medicamentos que han sido aprobados por las agencias reguladoras se retiran del mercado debido a problemas de seguridad que no se identificaron durante los ensayos clínicos. Ejemplos notables incluyen el retiro del medicamento Vioxx de Merck por aumentar el riesgo de ataques cardíacos y accidentes cerebrovasculares. Estudios clínicos sesgados: Se han documentado casos en los que los resultados de estudios clínicos son manipulados o sesgados para favorecer los intereses de la empresa farmacéutica patrocinadora. Esto puede llevar a la aprobación de medicamentos que en realidad no son tan seguros o efectivos como se afirma. Implicaciones y Medidas Correctivas Los casos de fraude, estafas y mala praxis en la industria farmacéutica tienen implicaciones graves para la salud pública y la confianza en el sistema de atención médica. Para abordar estos problemas, se han tomado y se siguen tomando diversas medidas: Mayor transparencia: Las agencias reguladoras y las empresas farmacéuticas están bajo presión para aumentar la transparencia en la divulgación de datos de ensayos clínicos y en la presentación de informes sobre la seguridad y eficacia de los medicamentos. Regulaciones más estrictas: Se están implementando regulaciones más estrictas para prevenir la fijación de precios abusivos y para garantizar que los medicamentos se receten de manera adecuada y segura. Control de conflictos de interés: Se están adoptando medidas para controlar los conflictos de interés en la relación entre médicos y la industria farmacéutica, como la divulgación pública de las relaciones financieras. Mayor supervisión y sanciones: Las empresas y personas involucradas en prácticas fraudulentas o de mala praxis están siendo investigadas y, en algunos casos, enfrentan sanciones legales y multas significativas. Conclusión Si bien la mayoría de las empresas farmacéuticas están comprometidas con el desarrollo y la comercialización de tratamientos que mejoran la salud humana, los casos de fraude, estafas y mala praxis han sacudido la confianza del público en la industria. Es esencial continuar trabajando en la implementación de regulaciones más estrictas, la promoción de la transparencia y la ética, y la vigilancia constante para garantizar que los pacientes reciban medicamentos seguros y efectivos sin que se comprometa su bienestar en aras de las ganancias. ---------------------------------------------------------------------------------------------------------------- Antena Historia te regala 30 días PREMIUM, para que lo disfrutes https://www.ivoox.com/premium?affiliate-code=b4688a50868967db9ca413741a54cea5 ---------------------------------------------------------------------------------------- Produce Antonio Cruz Edita ANTENA HISTORIA Antena Historia (podcast) forma parte del sello iVoox Originals ---------------------------------------------------------------------------------------- web……….https://antenahistoria.com/ correo.....info@antenahistoria.com Facebook…..Antena Historia Podcast | Facebook Twitter…...https://twitter.com/AntenaHistoria Telegram…...https://t.me/foroantenahistoria DONACIONES PAYPAL...... https://paypal.me/ancrume ---------------------------------------------------------------------------------------- ¿QUIERES ANUNCIARTE en ANTENA HISTORIA?, menciones, cuñas publicitarias, programas personalizados, etc. Dirígete a Antena Historia - AdVoices Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

La industria farmacéutica desempeña un papel crucial en la sociedad al proporcionar medicamentos y tratamientos que mejoran y salvan vidas. Sin embargo, como en cualquier industria, también ha sido escenario de casos de fraude, estafas y mala praxis. Estos incidentes no solo erosionan la confianza del público en la industria, sino que también plantean cuestionamientos éticos sobre la priorización de las ganancias por encima de la salud y el bienestar de los pacientes. En este artículo, exploraremos algunos ejemplos notorios de fraudes, estafas y mala praxis en la industria farmacéutica, así como las implicaciones y las medidas tomadas para abordar estos problemas. Casos Emblemáticos de Fraude y Estafas Caso Turing Pharmaceuticals y el aumento de precios de Daraprim: En 2015, Turing Pharmaceuticals, dirigida por Martin Shkreli, adquirió los derechos del medicamento Daraprim, utilizado en el tratamiento de infecciones parasitarias. La compañía aumentó drásticamente el precio del medicamento en un 5,000%, lo que generó indignación pública y puso de relieve las prácticas de fijación de precios abusivas en la industria. Caso Insys Therapeutics y el opioidi OxyContin: Insys Therapeutics promovió de manera agresiva su fentanilo de acción rápida, Subsys, para el tratamiento del dolor, incluso cuando no estaba indicado. La compañía se enfrentó a acusaciones de sobornar a médicos para recetar el medicamento y participar en tácticas de marketing engañosas, lo que contribuyó a la crisis de opioides en Estados Unidos. Caso GlaxoSmithKline y el escándalo del Paxil: La compañía farmacéutica GlaxoSmithKline fue acusada de ocultar datos sobre la seguridad y eficacia del antidepresivo Paxil en pacientes jóvenes. También se reveló que GSK había sobornado a médicos y manipulado la información en beneficio propio. Casos de Mala Praxis y Fallos en la Investigación Retiro de medicamentos después de la aprobación: En ocasiones, medicamentos que han sido aprobados por las agencias reguladoras se retiran del mercado debido a problemas de seguridad que no se identificaron durante los ensayos clínicos. Ejemplos notables incluyen el retiro del medicamento Vioxx de Merck por aumentar el riesgo de ataques cardíacos y accidentes cerebrovasculares. Estudios clínicos sesgados: Se han documentado casos en los que los resultados de estudios clínicos son manipulados o sesgados para favorecer los intereses de la empresa farmacéutica patrocinadora. Esto puede llevar a la aprobación de medicamentos que en realidad no son tan seguros o efectivos como se afirma. Implicaciones y Medidas Correctivas Los casos de fraude, estafas y mala praxis en la industria farmacéutica tienen implicaciones graves para la salud pública y la confianza en el sistema de atención médica. Para abordar estos problemas, se han tomado y se siguen tomando diversas medidas: Mayor transparencia: Las agencias reguladoras y las empresas farmacéuticas están bajo presión para aumentar la transparencia en la divulgación de datos de ensayos clínicos y en la presentación de informes sobre la seguridad y eficacia de los medicamentos. Regulaciones más estrictas: Se están implementando regulaciones más estrictas para prevenir la fijación de precios abusivos y para garantizar que los medicamentos se receten de manera adecuada y segura. Control de conflictos de interés: Se están adoptando medidas para controlar los conflictos de interés en la relación entre médicos y la industria farmacéutica, como la divulgación pública de las relaciones financieras. Mayor supervisión y sanciones: Las empresas y personas involucradas en prácticas fraudulentas o de mala praxis están siendo investigadas y, en algunos casos, enfrentan sanciones legales y multas significativas. Conclusión Si bien la mayoría de las empresas farmacéuticas están comprometidas con el desarrollo y la comercialización de tratamientos que mejoran la salud humana, los casos de fraude, estafas y mala praxis han sacudido la confianza del público en la industria. Es esencial continuar trabajando en la implementación de regulaciones más estrictas, la promoción de la transparencia y la ética, y la vigilancia constante para garantizar que los pacientes reciban medicamentos seguros y efectivos sin que se comprometa su bienestar en aras de las ganancias. ---------------------------------------------------------------------------------------------------------------- Antena Historia te regala 30 días PREMIUM, para que lo disfrutes https://www.ivoox.com/premium?affiliate-code=b4688a50868967db9ca413741a54cea5 ---------------------------------------------------------------------------------------- Produce Antonio Cruz Edita ANTENA HISTORIA Antena Historia (podcast) forma parte del sello iVoox Originals ---------------------------------------------------------------------------------------- web……….https://antenahistoria.com/ correo.....info@antenahistoria.com Facebook…..Antena Historia Podcast | Facebook Twitter…...https://twitter.com/AntenaHistoria Telegram…...https://t.me/foroantenahistoria DONACIONES PAYPAL...... https://paypal.me/ancrume ---------------------------------------------------------------------------------------- ¿QUIERES ANUNCIARTE en ANTENA HISTORIA?, menciones, cuñas publicitarias, programas personalizados, etc. Dirígete a Antena Historia - AdVoices Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Michael Malice (“YOUR WELCOME”) welcomes biotech founder, Martin Shkreli, onto the show to talk about the Daraprim controversy, how hard it is to tell your side of the story when American media has already painted you as the enemy, and the one federal agency Martin surprisingly thinks is good at what they do. Martin and Michael also discuss his time in prison, and the one joke that led to his bail being revoked. linktr.ee/martinshkreli instagram.com/martinshkreli15/ youtube.com/channel/UCjYKsjt-7EDU78KEcVbhYnQ Order THE WHITE PILL: http://whitepillbook.com/ Order THE ANARCHIST HANDBOOK: https://www.amzn.com/B095DVF8FJ Order THE NEW RIGHT: https://amzn.to/2IFFCCu Order DEAR READER: https://t.co/vZfTVkK6qf?amp=1 https://twitter.com/michaelmalice https://instagram.com/michaelmalice https://malice.locals.com https://youtube.com/michaelmaliceofficial Intro song: "Out of Reach" by Legendary House Cats https://thelegendaryhousecats.bandcamp.com/ The newest episode of "YOUR WELCOME" releases on iTunes and YouTube every Thursday! Please subscribe and leave a review. This week's sponsors: 4Patriots – Survival Food Kits: 4Patriots.com, promo code: MALICE (10% off) Fum - The Natural Alternative: tryfum.com, promo code: MALICE (10% off) Patriot Gold Group – No Fee IRA: Call 888-505-9845 or visit malicegold.com (Free investor guide) PlutoTV – Streaming TV: Pluto.tv Progressive – Name Your Price Tool: progressive.com

My First Million Key Takeaways  Martin Shkreli worked for Jim Cramer's hedge fund when he was in high school Martin became a millionaire at the age of 29 when he took his pharma company public “PubMed is the government database of all scholastic biomedical literature – so 36 million papers. If you sit there long enough and you have the passion, you can become a billionaire.” – Martin Shkreli It is not a crime to choose the price of your product He was bothered by the politicians trying to take the right away from entrepreneurs to set the price of their products, what he calls “regulation by embarrassment” If the regulators can tell Martin Shkreli what the price of his product should be, what is stopping them from setting the price of the iPhone? How much should a drug cost if it prevents the need for getting a $1 million surgery?After raising the price of the drug, there were zero patients that were unable to get the drug He hoped his casualness would encourage them to do some research and find out that no one (other than the insurance companies) were affected by the price increase Modern CEOs are not allowed to have a real personality: no one in the corporate world is allowed to have an opinion because it might be held against them or their companyMagic happens when you provide capital to great people with great assetsHealthcare is more expensive than we'd like mostly because of the artificially constrained supply of healthcare professionals, according to Martin Shkreli  Read the full notes @ podcastnotes.orgEpisode 445: Shaan Puri (@ShaanVP) and Sam Parr (@TheSamParr) talk with Martin Shkreli (@marty_catboy), aka "the most hated man in America", about how he got started in pharma, his logic behind raising the price of Daraprim, why he spent time in prison, and what business he's starting now. Vote for MFM to win a Webby: mfmpod.com/webby Click here to sign up for our event in Austin, TX on Saturday April 29th: mfmpod.com/atx Want to see more MFM? Subscribe to the MFM YouTube channel here. Check Out Sam's Stuff: * Hampton * Ideation Bootcamp * Copy That Check Out Shaan's Stuff: * Power Writing Course * Daily Newsletter ----- Links: *Dr. Gupta AI *@martinshkreli15 (Instagram) * Do you love MFM and want to see Sam and Shaan's smiling faces? Subscribe to our Youtube channel. ------ Show Notes: (00:30) - Intro to Martin Shkreli (02:10) - When Martin worked with Jim Cramer (23:00) - How he turned $2M into $1B in pharma (35:40) - Why did you jack up the price of the drugs? (54:20) - What do you do with your money? (01:00:33) - The Fun Strikes Back Movement (01:08:30) - Introducing Martin's New Company: Dr. Gupta AI (01:33:50) - Who are your heroes? ------ Past guests on My First Million include Rob Dyrdek, Hasan Minhaj, Balaji Srinivasan, Jake Paul, Dr. Andrew Huberman, Gary Vee, Lance Armstrong, Sophia Amoruso, Ariel Helwani, Ramit Sethi, Stanley Druckenmiller, Peter Diamandis, Dharmesh Shah, Brian Halligan, Marc Lore, Jason Calacanis, Andrew Wilkinson, Julian Shapiro, Kat Cole, Codie Sanchez, Nader Al-Naji, Steph Smith, Trung Phan, Nick Huber, Anthony Pompliano, Ben Askren, Ramon Van Meer, Brianne Kimmel, Andrew Gazdecki, Scott Belsky, Moiz Ali, Dan Held, Elaine Zelby, Michael Saylor, Ryan Begelman, Jack Butcher, Reed Duchscher, Tai Lopez, Harley Finkelstein, Alexa von Tobel, Noah Kagan, Nick Bare, Greg Isenberg, James Altucher, Randy Hetrick and more. ----- Additional episodes you might enjoy: • #224 Rob Dyrdek - How Tracking Every Second of His Life Took Rob Drydek from 0 to $405M in Exits • #209 Gary Vaynerchuk - Why NFTS Are the Future • #178 Balaji Srinivasan - Balaji on How to Fix the Media, Cloud Cities & Crypto * #169 - How One Man Started 5, Billion Dollar Companies, Dan Gilbert's Empire, & Talking With Warren Buffett • ​​​​#218 - Why You Should Take a Think Week Like Bill Gates • Dave Portnoy vs The World, Extreme Body Monitoring, The Future of Apparel Retail, "How Much is Anthony Pompliano Worth?", and More • How Mr Beast Got 100M Views in Less Than 4 Days, The $25M Chrome Extension, and More

My First Million Key Takeaways  Martin Shkreli worked for Jim Cramer's hedge fund when he was in high school Martin became a millionaire at the age of 29 when he took his pharma company public “PubMed is the government database of all scholastic biomedical literature – so 36 million papers. If you sit there long enough and you have the passion, you can become a billionaire.” – Martin Shkreli It is not a crime to choose the price of your product He was bothered by the politicians trying to take the right away from entrepreneurs to set the price of their products, what he calls “regulation by embarrassment” If the regulators can tell Martin Shkreli what the price of his product should be, what is stopping them from setting the price of the iPhone? How much should a drug cost if it prevents the need for getting a $1 million surgery?After raising the price of the drug, there were zero patients that were unable to get the drug He hoped his casualness would encourage them to do some research and find out that no one (other than the insurance companies) were affected by the price increase Modern CEOs are not allowed to have a real personality: no one in the corporate world is allowed to have an opinion because it might be held against them or their companyMagic happens when you provide capital to great people with great assetsHealthcare is more expensive than we'd like mostly because of the artificially constrained supply of healthcare professionals, according to Martin Shkreli  Read the full notes @ podcastnotes.orgEpisode 445: Shaan Puri (@ShaanVP) and Sam Parr (@TheSamParr) talk with Martin Shkreli (@marty_catboy), aka "the most hated man in America", about how he got started in pharma, his logic behind raising the price of Daraprim, why he spent time in prison, and what business he's starting now. Vote for MFM to win a Webby: mfmpod.com/webby Click here to sign up for our event in Austin, TX on Saturday April 29th: mfmpod.com/atx Want to see more MFM? Subscribe to the MFM YouTube channel here. Check Out Sam's Stuff: * Hampton * Ideation Bootcamp * Copy That Check Out Shaan's Stuff: * Power Writing Course * Daily Newsletter ----- Links: *Dr. Gupta AI *@martinshkreli15 (Instagram) * Do you love MFM and want to see Sam and Shaan's smiling faces? Subscribe to our Youtube channel. ------ Show Notes: (00:30) - Intro to Martin Shkreli (02:10) - When Martin worked with Jim Cramer (23:00) - How he turned $2M into $1B in pharma (35:40) - Why did you jack up the price of the drugs? (54:20) - What do you do with your money? (01:00:33) - The Fun Strikes Back Movement (01:08:30) - Introducing Martin's New Company: Dr. Gupta AI (01:33:50) - Who are your heroes? ------ Past guests on My First Million include Rob Dyrdek, Hasan Minhaj, Balaji Srinivasan, Jake Paul, Dr. Andrew Huberman, Gary Vee, Lance Armstrong, Sophia Amoruso, Ariel Helwani, Ramit Sethi, Stanley Druckenmiller, Peter Diamandis, Dharmesh Shah, Brian Halligan, Marc Lore, Jason Calacanis, Andrew Wilkinson, Julian Shapiro, Kat Cole, Codie Sanchez, Nader Al-Naji, Steph Smith, Trung Phan, Nick Huber, Anthony Pompliano, Ben Askren, Ramon Van Meer, Brianne Kimmel, Andrew Gazdecki, Scott Belsky, Moiz Ali, Dan Held, Elaine Zelby, Michael Saylor, Ryan Begelman, Jack Butcher, Reed Duchscher, Tai Lopez, Harley Finkelstein, Alexa von Tobel, Noah Kagan, Nick Bare, Greg Isenberg, James Altucher, Randy Hetrick and more. ----- Additional episodes you might enjoy: • #224 Rob Dyrdek - How Tracking Every Second of His Life Took Rob Drydek from 0 to $405M in Exits • #209 Gary Vaynerchuk - Why NFTS Are the Future • #178 Balaji Srinivasan - Balaji on How to Fix the Media, Cloud Cities & Crypto * #169 - How One Man Started 5, Billion Dollar Companies, Dan Gilbert's Empire, & Talking With Warren Buffett • ​​​​#218 - Why You Should Take a Think Week Like Bill Gates • Dave Portnoy vs The World, Extreme Body Monitoring, The Future of Apparel Retail, "How Much is Anthony Pompliano Worth?", and More • How Mr Beast Got 100M Views in Less Than 4 Days, The $25M Chrome Extension, and More

My First Million Key Takeaways  Martin Shkreli worked for Jim Cramer's hedge fund when he was in high school Martin became a millionaire at the age of 29 when he took his pharma company public “PubMed is the government database of all scholastic biomedical literature – so 36 million papers. If you sit there long enough and you have the passion, you can become a billionaire.” – Martin Shkreli It is not a crime to choose the price of your product He was bothered by the politicians trying to take the right away from entrepreneurs to set the price of their products, what he calls “regulation by embarrassment” If the regulators can tell Martin Shkreli what the price of his product should be, what is stopping them from setting the price of the iPhone? How much should a drug cost if it prevents the need for getting a $1 million surgery?After raising the price of the drug, there were zero patients that were unable to get the drug He hoped his casualness would encourage them to do some research and find out that no one (other than the insurance companies) were affected by the price increase Modern CEOs are not allowed to have a real personality: no one in the corporate world is allowed to have an opinion because it might be held against them or their companyMagic happens when you provide capital to great people with great assetsHealthcare is more expensive than we'd like mostly because of the artificially constrained supply of healthcare professionals, according to Martin Shkreli  Read the full notes @ podcastnotes.orgEpisode 445: Shaan Puri (@ShaanVP) and Sam Parr (@TheSamParr) talk with Martin Shkreli (@marty_catboy), aka "the most hated man in America", about how he got started in pharma, his logic behind raising the price of Daraprim, why he spent time in prison, and what business he's starting now. Vote for MFM to win a Webby: mfmpod.com/webby Click here to sign up for our event in Austin, TX on Saturday April 29th: mfmpod.com/atx Want to see more MFM? Subscribe to the MFM YouTube channel here. Check Out Sam's Stuff: * Hampton * Ideation Bootcamp * Copy That Check Out Shaan's Stuff: * Power Writing Course * Daily Newsletter ----- Links: *Dr. Gupta AI *@martinshkreli15 (Instagram) * Do you love MFM and want to see Sam and Shaan's smiling faces? Subscribe to our Youtube channel. ------ Show Notes: (00:30) - Intro to Martin Shkreli (02:10) - When Martin worked with Jim Cramer (23:00) - How he turned $2M into $1B in pharma (35:40) - Why did you jack up the price of the drugs? (54:20) - What do you do with your money? (01:00:33) - The Fun Strikes Back Movement (01:08:30) - Introducing Martin's New Company: Dr. Gupta AI (01:33:50) - Who are your heroes? ------ Past guests on My First Million include Rob Dyrdek, Hasan Minhaj, Balaji Srinivasan, Jake Paul, Dr. Andrew Huberman, Gary Vee, Lance Armstrong, Sophia Amoruso, Ariel Helwani, Ramit Sethi, Stanley Druckenmiller, Peter Diamandis, Dharmesh Shah, Brian Halligan, Marc Lore, Jason Calacanis, Andrew Wilkinson, Julian Shapiro, Kat Cole, Codie Sanchez, Nader Al-Naji, Steph Smith, Trung Phan, Nick Huber, Anthony Pompliano, Ben Askren, Ramon Van Meer, Brianne Kimmel, Andrew Gazdecki, Scott Belsky, Moiz Ali, Dan Held, Elaine Zelby, Michael Saylor, Ryan Begelman, Jack Butcher, Reed Duchscher, Tai Lopez, Harley Finkelstein, Alexa von Tobel, Noah Kagan, Nick Bare, Greg Isenberg, James Altucher, Randy Hetrick and more. ----- Additional episodes you might enjoy: • #224 Rob Dyrdek - How Tracking Every Second of His Life Took Rob Drydek from 0 to $405M in Exits • #209 Gary Vaynerchuk - Why NFTS Are the Future • #178 Balaji Srinivasan - Balaji on How to Fix the Media, Cloud Cities & Crypto * #169 - How One Man Started 5, Billion Dollar Companies, Dan Gilbert's Empire, & Talking With Warren Buffett • ​​​​#218 - Why You Should Take a Think Week Like Bill Gates • Dave Portnoy vs The World, Extreme Body Monitoring, The Future of Apparel Retail, "How Much is Anthony Pompliano Worth?", and More • How Mr Beast Got 100M Views in Less Than 4 Days, The $25M Chrome Extension, and More

Martin Shkreli is an American Investor, Pharmaceutical Executive and Hedge Fund Manager who became the most hated man in America in 2015 when he obtained the drug Daraprim and increased its price from $13.50 a pill, to $750 overnight. 0:00 Intro 1:56 The Big Short 8:04 How to price a drug 20:01 Should we price drugs like iPhones 25:36 Pharma's dirty secret with R&D spend 34:12 Why are we not discovering more drugs? Eroom's Law 43:59 Marting's new AI Doctor — Dr Gupta 51:08 What's the FDA going to say? 53:26 Problems with GPT-4; hallucinations and sources 1:00:00 Mental health impact of being the most hated man in America 1:02:30 How rich are you? 1:08:00 Outro Daraprim is used to treat or prevent parasitic diseases, commonly in patients with HIV or AIDS. He defended the move by saying “If there was a company that was selling an Aston Martin at the price of a bicycle, and we buy that company and we ask to charge Toyota prices, I don't think that that should be a crime.” Unrelated to the Daraprim scandal, in 2017 he was charged with securities fraud and sentenced to seven years in prison and fined a total of over $70M dollars. Martin comes from humble beginnings, his parents are Albanian immigrants — but he quickly ascended the world and became a multimillionaire polymath. And despite having no formal training in Medical Sciences — he has a penchant for consuming medical literature from PubMed, and making novel insights. We talk about how Martin does this, his philosophy around drug pricing — and whether we should think about pricing drugs in the same way we price iPhones, we talk about whether blowing more money into pharma research & development actually leads to more exciting drugs, Martin's new AI doctor that he just launched and the mental health impact of being the world's most hated man. You can find me on Twitter @MustafaSultan and subscribe to my newsletter on www.musty.io

Episode 445: Shaan Puri (@ShaanVP) and Sam Parr (@TheSamParr) talk with Martin Shkreli (@marty_catboy), aka "the most hated man in America", about how he got started in pharma, his logic behind raising the price of Daraprim, why he spent time in prison, and what business he's starting now. Vote for MFM to win a Webby: mfmpod.com/webby Click here to sign up for our event in Austin, TX on Saturday April 29th: mfmpod.com/atx Want to see more MFM? Subscribe to the MFM YouTube channel here. Check Out Sam's Stuff: * Hampton * Ideation Bootcamp * Copy That Check Out Shaan's Stuff: * Power Writing Course * Daily Newsletter ----- Links: *Dr. Gupta AI *@martinshkreli15 (Instagram) * Do you love MFM and want to see Sam and Shaan's smiling faces? Subscribe to our Youtube channel. ------ Show Notes: (00:30) - Intro to Martin Shkreli (02:10) - When Martin worked with Jim Cramer (23:00) - How he turned $2M into $1B in pharma (35:40) - Why did you jack up the price of the drugs? (54:20) - What do you do with your money? (01:00:33) - The Fun Strikes Back Movement (01:08:30) - Introducing Martin's New Company: Dr. Gupta AI (01:33:50) - Who are your heroes? ------ Past guests on My First Million include Rob Dyrdek, Hasan Minhaj, Balaji Srinivasan, Jake Paul, Dr. Andrew Huberman, Gary Vee, Lance Armstrong, Sophia Amoruso, Ariel Helwani, Ramit Sethi, Stanley Druckenmiller, Peter Diamandis, Dharmesh Shah, Brian Halligan, Marc Lore, Jason Calacanis, Andrew Wilkinson, Julian Shapiro, Kat Cole, Codie Sanchez, Nader Al-Naji, Steph Smith, Trung Phan, Nick Huber, Anthony Pompliano, Ben Askren, Ramon Van Meer, Brianne Kimmel, Andrew Gazdecki, Scott Belsky, Moiz Ali, Dan Held, Elaine Zelby, Michael Saylor, Ryan Begelman, Jack Butcher, Reed Duchscher, Tai Lopez, Harley Finkelstein, Alexa von Tobel, Noah Kagan, Nick Bare, Greg Isenberg, James Altucher, Randy Hetrick and more. ----- Additional episodes you might enjoy: • #224 Rob Dyrdek - How Tracking Every Second of His Life Took Rob Drydek from 0 to $405M in Exits • #209 Gary Vaynerchuk - Why NFTS Are the Future • #178 Balaji Srinivasan - Balaji on How to Fix the Media, Cloud Cities & Crypto * #169 - How One Man Started 5, Billion Dollar Companies, Dan Gilbert's Empire, & Talking With Warren Buffett • ​​​​#218 - Why You Should Take a Think Week Like Bill Gates • Dave Portnoy vs The World, Extreme Body Monitoring, The Future of Apparel Retail, "How Much is Anthony Pompliano Worth?", and More • How Mr Beast Got 100M Views in Less Than 4 Days, The $25M Chrome Extension, and More

Martin Shkreli was once branded the most hated CEO in USA history. He got this title when he infamously increased the price of Daraprim from $13.50 to $750 per pill. Different Lawsuits soon came in, and he was eventually jailed for 7 years. But was Martin Shkreli as evil as the media portrays him to be? Why did he raise the drug prices? What is his side of the story? Martin Shkreli himself joined me on the Survival Skills Podcast where he talked about his side of the story, why he was jailed, what life was like in prison And his opinion on cryptocurrencies. Watch the video version of this episode on Youtube    Click Here

In September 2015, Martin Shkreli quickly became ‘the most hated man in America' after he raised the price of the life-saving drug, Daraprim, by more than 4,000% - almost overnight. Instead of apologising or hiding away, Shkreli decided to lean into his villain image, with even more media appearances and antagonising acts. In an interview with The Hustle magazine, Shkreli was quoted as saying: “People want a villain,” “If people derive some psychological benefit from that, then I don't want to deprive them of it. I'll be your villain.” Shkreli lied with regularity, harassed female journalists and even took on the Wu-Tang Clan. At his securities fraud trial almost 200 jurors were ‘excused' during jury selection because as one juror said: “The only thing I'd be impartial about is what prison this guy goes to.” In part two, Dr Julia Shaw and Sofie Hagen discuss the latest research on ‘hate'. Why do we hate? Whom do we hate? And can one love to be hated? They also talk about jury selection and whether it is ever possible to have a completely unbiased jury.CREDITS Presenters: Dr Julia Shaw and Sofie Hagen Producer: Simona Rata Music: Matt Chandler Editor: Anna Lacey #BadPeople_BBC Commissioning Assistant Producer: Adam Eland Commissioning Executive: Dylan Haskins Bad People is produced in partnership with The Open University and is a BBC Audio Science Production for BBC Sounds.

In September 2015, Martin Shkreli's name made headlines. He quickly became ‘the most hated man in America' after he raised the price of the life-saving drug, Daraprim, by more than 4,000% - almost overnight. He was vilified by the press and the public alike and was often referred to as ‘pharma bro', a representation of everything that was seemingly wrong with Big Pharma. Was Martin Shkreli unfairly singled out? How was any of it legal? And is ruthlessness in business justified?This is part one of two. On this episode of Bad People Dr Julia Shaw and Sofie Hagen discuss greed and whether it's inherently bad. This episode includes audio from the 2021 documentary ‘Pharma Bro' by Blumhouse Productions, directed by Brent Hodge. CREDITS Presenters: Dr Julia Shaw and Sofie Hagen Producer: Simona Rata Music: Matt Chandler Editor: Anna Lacey #BadPeople_BBC Commissioning Assistant Producer: Adam Eland Commissioning Executive: Dylan Haskins Bad People is produced in partnership with The Open University and is a BBC Audio Science Production for BBC Sounds.

Martin Shkreli IS THE FREAKING WORST! The 38-year-old financial entrepreneur and pharmaceutical tycoon from Brooklyn was dubbed "the most hated man in America"  in 2015 for price gouging the prescription drug Daraprim by 5500% overnight depriving AIDS patients, people with cancer, and pregnant people of the life-saving medication. That same year, Shkreli purchased the Wu-Tang Clan's single copy of "Once Upon a Time in Shaolin" for 2 million dollars, AND THEN TALKED TRASH ABOUT WU -TANG EVERY CHANCE HE GOT. Prepare to get fired up, Fam! HERE ARE OUR ADDED TOUR DATES!!--PATRICK IS HITTING THE ROAD WITH  MAGGIE, AND LANCE & TIM TO DO THE LIVE SHOW COVERING "THE DISAPPEARANCE OF MAURA MURRAY." Gillian will not be joining us BUT SHE LOVES YOU AND CAN'T WAIT TO SEE YOU AT OBSESSED FEST! Wednesday, August 3: Orlando, FL Thursday, August 4: West Palm Beach, FL Saturday, August 6: Atlanta, Georgia Friday, August 19: St. Paul, MN Saturday, August 20: Dallas, TX Sunday, August 21: Houston TX LOOKING FOR MORE TCO? On our Patreon feed, you'll find over 300 FULL BONUS episodes to BINGE RIGHT NOW! Including our episode-by-episode coverage of "LuLaRich" "John Wayne Gacy: Devil in Disguise" "Night Stalker" "The Jinx," "Making A Murderer," "The Staircase," "I'll Be Gone in the Dark," "A Wilderness of Error" "The Vow"  "Tiger King" "Don't F**K With Cats," "The Menendez Murders," "The Murder of Laci Peterson," "Casey Anthony: American Murder Mystery," "Serial," "Lorena," "The Disappearance of Madeleine McCann," "OJ: Made in America" and so many more! JOIN HERE! COME TO OBSESSED FEST!! It's the first-ever OBSESSED NETWORK FAMILY WEEKEND! It's going to be a weekend full of live shows--OWD Friday night, TCO Saturday night (and two non-Obsessed Network live shows as well!), meet & greets, KARAOKE!, meetups, panel chats AND. ONE. INSANE. DRAG. BRUNCH!!! It's all happening at the Hyatt Regency in Columbus, Ohio from September 30 - October 2nd. TICKETS ARE ALMOST GONE!! GET YOUR TICKET

Martin Shkreli, ‘the most hated man in America', purchased the one extant copy of the Wu-Tang Clan's concept album ‘Once Upon A Time In Shaolin' for $2 million on 3rd May, 2015.  In seeking to sell their record in an auction, the hip-hop collective had been inspired by the concept of wealthy patrons funding Renaissance artists - but hadn't counted on the winning bidder being the ‘pharma bro' notorious for raising the price of toxoplasmosis drug Daraprim by a factor of 56. In this episode, Arion, Rebecca and Olly consider whether Shkreli's ‘price gouging' antics made him an (in)appropriate buyer; ask whether it can really be true that the multimillionaire didn't even bother listening to his purchase; and explain what happened to the CD after Shkreli was imprisoned for fraud… Further Reading: • Everything I Know About the Wu-Tang Album from Hanging Out with Martin Shkreli (VICE, 2016): https://www.vice.com/en/article/3bjmq9/everything-i-know-about-the-wu-tang-clan-album-from-hanging-out-with-martin-shkreli • ‘Wu-Tang clap back, dissing Martin Shkreli on new track' (The Guardian, 2017): https://amp.theguardian.com/us-news/2017/sep/22/wu-tang-clan-martin-shkreli-track • ‘Martin Shkreli on Drug Price Hikes and Playing the World's Villain' (VICE, 2016): https://www.youtube.com/watch?v=2PCb9mnrU1g For bonus material and to support the show, visit Patreon.com/Retrospectors We'll be back tomorrow! Follow us wherever you get your podcasts: podfollow.com/Retrospectors The Retrospectors are Olly Mann, Rebecca Messina & Arion McNicoll, with Matt Hill. Theme Music: Pass The Peas. Announcer: Bob Ravelli. Graphic Design: Terry Saunders. Edit Producer: Alexa Weissman. Copyright: Rethink Audio / Olly Mann 2022. Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit podcastchoices.com/adchoices

If ever there was a villain origin story...this is it. Pharma Bro is a profiling of the notorious Martin Shkreli, the pharmaceutical tycoon and resident weirdo from Brooklyn, New York. You may remember him from hits like raising the cost of Daraprim by 5000% or from buying the infamous Wu Tang Clan album for 2 million to use it as a coaster. What's even more baffling are the lengths the filmmaker went to get up close and personal with this myth of a man.

If ever there was a villain origin story...this is it. Pharma Bro is a profiling of the notorious Martin Shkreli, the pharmaceutical tycoon and resident weirdo from Brooklyn, New York. You may remember him from hits like raising the cost of Daraprim by 5000% or from buying the infamous Wu Tang Clan album for 2 million to use it as a coaster. What's even more baffling are the lengths the filmmaker went to get up close and personal with this myth of a man.

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Act of Charity , published by jessicata on the LessWrong. (Cross-posted from my blog) The stories and information posted here are artistic works of fiction and falsehood. Only a fool would take anything posted here as fact. Anonymous Act I. Carl walked through the downtown. He came across a charity stall. The charity worker at the stall called out, "Food for the Africans. Helps with local autonomy and environmental sustainability. Have a heart and help them out." Carl glanced at the stall's poster. Along with pictures of emaciated children, it displayed infographics about how global warming would cause problems for African communities' food production, and numbers about how easy it is to help out with money. But something caught Carl's eye. In the top left, in bold font, the poster read, "IT IS ALL AN ACT. ASK FOR DETAILS." Carl: "It's all an act, huh? What do you mean?" Worker: "All of it. This charity stall. The information on the poster. The charity itself. All the other charities like us. The whole Western idea of charity, really." Carl: "Care to clarify?" Worker: "Sure. This poster contains some correct information. But a lot of it is presented in a misleading fashion, and a lot of it is just lies. We designed the poster this way because it fits with people's idea is of a good charity they should give money to. It's a prop in the act." Carl: "Wait, the stuff about global warming and food production is a lie?" Worker: "No, that part is actually true. But in context we're presenting it as some kind of imminent crisis that requires an immediate infusion of resources, when really it's a very long-term problem that will require gradual adjustment of agricultural techniques, locations, and policies." Carl: "Okay, that doesn't actually sound like more of a lie than most charities tell." Worker: "Exactly! It's all an act." Carl: "So why don't you tell the truth anyway?" Worker: "Like I said before, we're trying to fit with people's idea of what a charity they should give money to looks like. More to the point, we want them to feel compelled to give us money. And they are compelled by some acts, but not by others. The idea of an immediate food crisis creates more moral and social pressure towards immediate action, than the idea that there will be long-term agricultural problems that require adjustments. Carl: "That sounds...kind of scammy?" Worker: "Yes, you're starting to get it! The act is about violence! It's all violence!" Carl: "Now hold on, that seems like a false equivalence. Even if they were scammed by you, they still gave you money of their own free will." Worker: "Most people, at some level, know we're lying to them. Their eyes glaze over 'IT IS ALL AN ACT' as if it were just a regulatory requirement to put this on charity posters. So why would they give money to a charity that lies to them? Why do you think?" Carl: "I'm not nearly as sure as you that they know this! Anyway, even if they know at some level it's a lie, that doesn't mean they consciously know, so to their conscious mind it seems like being completely heartless." Worker: "Exactly, it's emotional blackmail. I even say 'Have a heart and help them out'. So if they don't give us money, there's a really convenient story that says they're heartless, and a lot of them will even start thinking about themselves that way. Having that story told about them opens them up to violence." Carl: "How?" Worker: "Remember Martin Shkreli?" Carl: "Yeah, that asshole who jacked up the Daraprim prices." Worker: "Right. He ended up going to prison. Nominally, it was for securities fraud. But it's not actually clear that whatever security fraud he did was worse than what others in his industry were doing. Rather, it seems likely that he was especially targeted because he was a heartless asshole." Carl: "But he still brok...

Sam and Thomas discuss the Epstein/Maxwell child sex trafficking trial, the people killed in the Champlain Towers Collapse, Pharma Bro Martian Shkreli's Anti-Parasitic Drug Daraprim and much more… Broadcasting in the California Central Valley Here: Comcast Xfinity Ch. 93, AT&T U-Verse Ch. 99 Cablecast app on Roku or Apple TV https://cmac.tv/apps/ https://cmac.tv/series/weaponized-news/ Share and Follow and Subscribe to: Thomas Alpha Omega Energy "We Changed The World!" +855 818 55 800 (Also Whatsapp) aomegaenergy.com Twitter: https://twitter.com/AOECOINnews Telegram: AlphaOmegaEnergy Share and Follow and Subscribe to Weaponized News http://weaponizednews.com/ https://anchor.fm/weaponizednews https://www.brighteon.com/channels/weaponizednews https://odysee.com/@WeaponizedNews:6 https://www.bitchute.com/channel/t8y7ptaYWaFl/ https://gab.com/WeaponizedNews https://twitter.com/WeaponizedNews Help the Weaponized News Pay Some Bills Donate https://www.paypal.com/donate?token=SMJThaUrGts7xg3e2v_QRwXmPibJym12pzJPcjpi9xwKo1HAm0WlcJUal43SKOErssQYynjCc6t8DGoC Bitcoin 36fNy89D8vnmH2Ty14ceeoaoomHzGvsH8o Ethereum 0x5dAE62B94C83290dB599A4917003db95EeC365B6 XRP rw2ciyaNshpHe7bCHo4bRWq6pqqynnWKQg:::ucl:::714284265

PHARMA BRO chronicles the shooting star life and times of Martin Shkreli, the 38-year-old financial entrepreneur and pharmaceutical tycoon from Brooklyn, New York, was dubbed “the most hated man in America” by the media after he rose to infamy in 2015 for price gouging the prescription drug Daraprim by 5500% overnight depriving patients of the life-saving medication. Hodge presents a new in-depth look on the all-too familiar media tale in PHARMA BRO a concentrated year-long study of the man who defies traditional categorization. Through traveling to Shkrel, Albania to learn about his heritage and uncover his backstory; visiting hospitals and talking with Daraprim patients; watching countless hours of his live-stream; and uncovering the real story about the Wu-Tang album, Hodge is able to provide new and alternative insight from a variety of sources, who offer commentary on Shkreli and his story of promising financial savant turned pharma opportunist and the fortune he acquired at the detriment of others. Combining live streams, sit-down interviews, news footage, filmed scenes and actual encounters with Shkreli, Hodge presents a prismatic image of PHARMA BRO, the differing sides he consciously (and sometimes unconsciously) presented and a cinematic examination of the qualities that earned him his most hated status. The film features Wu-Tang Clan's Ghostface Killah, musical artist The Fridge, Journalist Christie Smythe, and Shkreli Defense Attorney Ben Brafman. Director Brent Hodge (A Brony Tale, I Am Chris Farley, Freaks and Geeks: The Documentary) joins us for a lively conversation on why he wanted to go behind the headlines to explore the how and why of the Shkreli's life as well as his personal commitment to being even-handed in telling the whole story of “the most hated man in America.” For news and updates go to: 1091pictures.com

Martin Shkreli became infamous as the smug “pharma bro” who raised the price of HIV drug Daraprim from $13.50 to $750.00 per tablet. But is he evil? Or is he the inevitable outcome of America's poorly regulated pharmaceutical industry? And what about that $2 million Wu-Tang Clan album he bought? Or the Bloomberg journalist who fell in love with him? This week, Evil Men takes a nice, juicy look at currently incarcerated cartoon villain Martin Shkreli. Enjoy! PLUS: Chris talks about getting retweeted by Flea, Michael reflects on “white boy summer” and James goes to a baseball game. Support Evil Men on Patreon for exclusive monthly bonus episodes and SPECIAL  MATERIAL. Follow Evil Men on Twitter and Instagram. And rate and review us wherever possible! Brought to you By: The Sonar Network

Martin Shkreli became infamous as the smug “pharma bro” who raised the price of HIV drug Daraprim from $13.50 to $750.00 per tablet. But is he evil? Or is he the inevitable outcome of America's poorly regulated pharmaceutical industry? And what about that $2 million Wu-Tang Clan album he bought? Or the Bloomberg journalist who fell in love with him? This week, Evil Men takes a nice, juicy look at currently incarcerated cartoon villain Martin Shkreli. Enjoy!PLUS: Chris talks about getting retweeted by Flea, Michael reflects on “white boy summer” and James goes to a baseball game.Support Evil Men on Patreon for exclusive monthly bonus episodes and SPECIAL  MATERIAL.Follow Evil Men on Twitter and Instagram. And rate and review us wherever possible!Brought to you By: The Sonar Network Hosted on Acast. See acast.com/privacy for more information.

El derecho tiene un poco de arte y un poco de ciencia, los argumentos y las pruebas hacen o deshacen un caso. Navegamos en el libro "Copycat: La delgada línea de la Propiedad Intelectual (Un compendio de propiedad intelectual nº 8)" junto a su autor Ricardo Rodríguez, quien nos habla de la Propiedad Intelectual vista desde otras perspectivas y usando términos del mundo de los negocios y la mercadotecnia. 

Although there is little question as to the need for affordable, accessible, and high-quality pharmaceuticals, there is immense disagreement as to how best to achieve that end. What are the key issues facing pharmaceutical antitrust enforcement today? Michael Kades, Director of Markets and Competition Policy for the Washington Center for Equitable Growth, joins Christina Ma and John Roberti to discuss the current state of pay-for-delay, the FTC's Daraprim case, FTC restitution before SCOTUS, and biologics. Listen to this episode for a quick primer on things to pass and things to come in pharmaceutical antitrust enforcement. Related Links: https://equitablegrowth.org/competitive-edge-underestimating-the-cost-of-underenforcing-u-s-antitrust-laws/ https://equitablegrowth.org/congress-adopts-historic-prescription-drug-pricing-reform/ https://www.ftc.gov/system/files/documents/cases/2020.01.27_daraprim_complaint_final_redacted.pdf https://www.supremecourt.gov/DocketPDF/19/19-825/126165/20191219140044609_No.%2019-__%20PetitionForAWritOfCertiorari%20and%20Appendix%20FTC%20v.%20Credit%20Bureau%20Center.pdf Hosted by: Christina Ma, Associate, Wachtell Lipton Rosen & Katz and John Roberti, Partner, Allen & Overy

'After all, isn't sharing knowledge and discovery what science is really all about?' This program first aired September 23, 2018

'After all, isn't sharing knowledge and discovery what science is really all about?' This program first aired September 23, 2018

A Revolution in American Medicine is Long Overdue Richard Gale and Gary Null PhD July 6, 2020   The sweeping occurrence of CoV19 infections has contributed to a loss of jobs, careers, regular education for our children and has adversely impacted the health of otherwise healthy people. But for tens of millions of Americans who have lost their health insurance or have not been covered, the situation is more dire. One illness, one infectious disease, could push them over the edge into insolvency and bankruptcy. Now is the opportune time to change course, bail out all Americans and cease providing taxpayer gifts to Wall Street, the rich and powerful.  The fundamental problem with Obamacare, and the proposed combination of a Green New Deal and Medicare for All, is that both leave the unconscionable profit making in the system. The medical lobbies, insurance and hospital industries and Big Pharma assure that if you are hospitalized with CoV19 and don't have insurance, you will receive a bill for tens of thousands of dollars. There is no power in the US at this moment that would prevent these private industries from foregoing a $3.5 trillion windfall profit annually. Therefore the Democrats who claim they want universal healthcare want it only on the condition that the existing system is not upended. Yet that is exactly what is demanded at this moment. The onslaught of misinformation from the corporatist wings of both political parties and media biases against universal healthcare are obviously confusing the electorate. This confusion leaves citizens bewildered about how they will pay their bills unless a fundamental overhaul of medical insurance is undertaken. More important, what will happen if you are diagnosed with a serious illness and are not fully covered? What are your chances of joining the ranks of the 530,000 families that file bankruptcy annually for medical reasons?  According to a study published last year by the American Journal of Public Health, 66.5% of bankruptcies are medically-related.  In the past, it was rare for people to go bankrupt because they did not have accessible medical care. There was a time in the US when medicine carried a higher standard of ethics. The Hippocratic Oath was respected and no one was denied medical care because they could not afford it.  But that was in the past. Obama's Affordable Care Act, which Biden continues to believe is a successful piece of legislation, has done little to mitigate the increasing financial burden on individuals and families. In fact, quality of healthcare has steadily declined. Now with the CoV19 pandemic, we are witnessing patients forced to pay out of pocket enormous bills for diagnostic testing, ER visits, hospitalization and treatments. If you are returning to the country from overseas, you may be forced to pay for the time spent in quarantine even if you test negative for the virus.  And the pharmaceutical and insurance industries are already capitalizing on this disaster. The Democrat Party's full throttle assault to undermine the legitimacy of Bernie Sanders' campaign was orchestrated by the insurance and medical industrial complex, which has influenced unbridled bias across the media waves. The goal is to effectively sustain Obama's failed healthcare efforts. After listening to dozens of commentators on CNN, MSNBC, Fox, and the pseudo-health journalists at the New York Times, and Washington Post, the false impression was created to perceive Bernie as only offering free stuff to everyone and at enormous cost to taxpayers.  No one truly knows how much a national universal program would cost. Forecasts for a 10-year period range roughly between $13 trillion and $48 trillion. One thing is certain. The math is simple. It would be extremely expensive and for it to succeed dramatic infrastructural changes would need to be made throughout the entire healthcare system and how medicine is conventionally practiced.  That conversation is long overdue. However, perhaps this is the wrong argument because it is based upon the Democratic Party's deep seated cognitive dissonance to protect the vested interests of Wall Street's financial community, Biden's allegiance to the credit lending industry, the military industrial complex, and the pharmaceutical and agro-chemical industries. In effect, the entirety of corporate America and the deep state, its lobbyists and oligarchic billionaires, and their sounding board in the mainstream media, are on one side of the scale while the urgent humanitarian medical needs of average citizens are on the other.  All that weighs on the side of Medicare for All are the educated adults, unionists, working people, and those who understand climate change and the need for a comprehensive and equitable healthcare system. This still remains to be a revolution that must take place across the nation. So, how does such a revolution get launched? First, Medicare for All is doable and affordable. In fact, it can potentially save $1.7 trillion a year by removing from the equation unnecessary and unconscionable profit to private insurance providers, the drug makers and the large mega-hospital networks.  There is no reason for having so many levels of bureaucracy between direct medical care and the patient. Every industry directly involved in providing treatment and care would continue to profit. But it would be a reasonable profit. Instead we have a medical lobby that is excessively greedy and eager to take advantage of loopholes in order to milk the system for whatever it is worth. But we can only have a viable Medicare for All after we seriously look at what it costs to treat a patient and make efforts to reduce the exorbitant waste that has been programmed into our current system. How is it that a hospital can charge $787 for an adult and $393 for a child for a one dollar bag of intravenous saline solution, plus an additional $127 to administer it? Americans spend more on prescription medications than any other developed nation, as drug prices can soar ten times the rate of inflation.  Daraprim, for example, which is prescribed to fight one of the world's most common parasitical infections that causes toxoplasmosis, can cost $45,000 per month, or $750 for a single pill that costs $13.50 to manufacture. When we consider the costs for treating CoV19, the figures get even more outrageous. An average Medicare payment for a common respiratory infection is about $13,300, and over $40,000 for an infection requiring a ventilator. That was in 2017, and the average costs have increased 20 percent or more in less than three years. Average out of pocket costs for being hospitalized for pneumonia is $1,300 and much higher for those covered by small business insurance. Cases of uninsured people being treated for Cov19 have received medical bills upwards to $35,000 and conservatively there are 28 million uninsured citizens in the US at this moment and rising as unemployment increases.  Consequently only 1 in 7 Americans polled would not seek CoV treatment because of the cost. Based upon earlier figures between 2012-2015, about $2.6 trillion can be saved by removing bureaucratic waste and profiteering. This includes $275 billion on private insurance paperwork, $55.6 billion on liability insurance, $471 billion for insurance billing, $140 billion for medical fraud (2016), $210 billion for unnecessary medical testing, and $190 billion for wasteful administrative services.  Back in 2016, the British Medical Journal reported that medical error is the third leading cause of death in the US.  As a result over $1 trillion is spent on avoidable medical errors.  Universal healthcare will not break the economy. What is breaking the economy is our current broken medical system.  Universal, quality care is easily within reach but only after the health of the population is given preference over the healthcare system's vulture capitalists. Then Americans will no longer have to worry about bankruptcy, which further contributes to the stresses associated with ill health, because they cannot afford the treatments or medications without putting themselves and their family into perpetual debt. Second, providing universal healthcare does not guarantee that patients will receive quality care. If we are truly honest with ourselves and ask whether the US has the best medical care available, the answer should be a resounding no.  American emergency medicine is exemplary as is specialized surgery. However, chronic care for treating heart disease, cancer, diabetes, pain management and neurological and mental health conditions has been a dismal failure. More physicians need to be brought into the system without the anxiety of paying off enormous school debt and being forced to work to exhaustion.  We would be wise to make medical education free in return for young doctors committing themselves to charging reasonable fees if they wish to remain within the system. If a doctor prefers to gouge patients, that is their right to do so outside of the national system. Finally, the US lags far behind in a implementing a national preventative program. Very little has been done to prevent diseases shown to be directly related to life-style, diet and toxic conditions in our environment.  A viable prevention program would begin by supporting and mandating holistic health programs in our schools beginning with grade school. Why does offering school courses in "How to be Healthy" seem absurd when it has been shown repeatedly in the scientific peer-review literature and efforts in other advanced nations to avoid preventable illnesses and further reduce medical costs? But in order to launch a comprehensive preventative  program at a national scale, only respected educated health consumers should be in charge. Entities representing private corporate interests should be prohibited since they are responsible for the medical disasters that now demand for universal healthcare.  If Obamacare and the current corporate medical establishment were truly effective, there would be no discussion about Medicare for All. Hence this program would save nearly $2 trillion a year and help prevent tens of millions of diseases. The nation would be much healthier if comprehensive measures were taken to prevent disease in the first place. During the past three years we have sent on multiple occasions suggestions for implementing a Medicare for All to the Sanders' campaign and leading Democrats in Congress. But not a single person has responded. What does that tell us about the sincerity and commitment of those who profess universal healthcare but get their funding and marching orders from the drug industry?   Richard Gale is the Executive Producer of the Progressive Radio Network and a former Senior Research Analyst in the biotechnology and genomic industries.   Dr. Gary Null is the host of the nation's longest running public radio program on alternative and nutritional health and a multi-award-winning documentary film director, including The War on Health, Poverty Inc and Plant Codes.

By his early 30s, Martin Shkreli had held a variety of impressive roles; he was the co-founder of multiple successful hedge funds, CEO of biotechnology firm Retrophin; and founder and CEO of Turing Pharmaceuticals. So, how did young Martin Shkreli, with no formal training in chemistry and a Bachelor's Degree in business administration, become a pharmaceutical CEO and have an estimated worth by Fortune magazine in 2016 of $45 million? And how did Martin Shkreli only a few years later become a convicted felon worth practically nothing; referred to by the media as "Pharma Bro" and "the most hated man in America"? And whatever happened to that unreleased Wu Tang Clan Album Martin Shkreli bought for $2 million? Find out today on the Controversial Figures Podcast.Connect with us on Twitter: https://twitter.com/FiguresPodcastEpisode Sources:CNBC https://www.cnbc.com/2019/08/07/retrophin-paid-martin-shkreli-to-settle-all-legal-claims.htmlNetFlix Dirty Money, Drug Short episodeVanity Fair https://www.vanityfair.com/news/2015/12/martin-shkreli-pharmaceuticals-ceo-interviewWikipediaMartin Shkreli https://en.wikipedia.org/wiki/Martin_ShkreliNaked Short Sell https://en.wikipedia.org/wiki/Naked_short_sellingOnce Upon a Time in Shaolin https://en.wikipedia.org/wiki/Once_Upon_a_Time_in_ShaolinXconomy https://xconomy.com/san-diego/2019/08/22/retrophin-sinks-as-drug-pharma-bro-martin-shkreli-co-invented-fails/ Music: The 6 is Silent by SkyjellyBuzzsprout - Let's get your podcast launched! Start for FREEDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the show (https://www.patreon.com/controversialfigurespod)

Today we talk about the ban on certain electrical stimulation devices, the latest COVID-19 news, a first generic of Daraprim, a New Drug Application for a potential microneedle migraine treatment patch, and a first over-the-counter combination of ibuprofen and acetaminophen: Advil Dual Action.

HAPPY NEW YEAR A Decade Marked By Outrage Over Drug Prices Martin Shkreli, the former CEO of Turing Pharmaceuticals, who was called before Cummings' committee in2016. After hiking the price of an old drug for parasitic infections to $750 a pill from $13.50, Shkreli became the poster boy for pharmaceutical greed that helped define the past decade. Meanwhile, nearly 1 in 4 Americans has trouble affording prescription drugs, according to a Kaiser Family Foundation poll. Of relevance, perhaps to our NA members, Daraprim: An old drug gets a huge new price For decades, Daraprim has been the go-to medicine for treating toxoplasmosis, a parasitic infection especially dangerous for people with compromised immune systems, such as people living with HIV and patients who've undergone organ transplants. The drug was approved by the Food and Drug Administration in 1953, and its patents expired long ago. But there wasn't a generic version available, and there was only one supplier in the United States. Even so, Daraprim cost just $13.50 a pill in early 2015. Then Turing Pharmaceuticals bought the rights to the drug and raised its list price more than 5,000% overnight. Another company called Valeant did the same year when it bought two old heart drugs — Isuprel and Nitropress — that had little competition. Despite public outcry, Daraprim's price hasn't budged. Today, many health insurance companies won't pay for the drug, and it's too expensive for many hospitals to keep in stock, says Armstrong. As a result, she says, doctors have been forced to turn to cheaper alternatives that have more side effects and less proof that they work. Then there is EpiPen, used to counteract allergic reactions. By the time the EpiPen's list price reached $300 per auto-injector in 2016, its manufacturer, Mylan, had made more than a dozen price hikes in just six years. People clamored for a cheaper generic of the product, which injects a dose of epinephrine to counteract allergic reactions. Mylan had a virtual monopoly on it. In the spring of 2016, the FDA had rejected two applications from other firms that wanted to make generic versions. State and federal lawmakers took notice. For years, they had been passing laws that pushed for schools and other public places to have EpiPens on hand. Mylan started offering its own generic at half the price in December 2016 and left the price of its brand-name product where it was. Mylan's new version is called an authorized generic. These are usually introduced to undercut competition from other companies' generics — and eat into some of the competitors' profits. Next consider Sovaldi: a first-of-its-kind hepatitis C drug, priced at $1,000 per pill. To rid a patient of the hepatitis C virus would cost $84,000 per person. State health systems struggled to pay for the treatment, and health insurers denied the drug to all but the sickest patients. An investigation led by Iowa Republican Sen. Chuck Grassley and Oregon Democratic Sen. Ron Wyden found that state Medicaid programs spent more than $1 billion on the drug in 2014, but less than 2.4% of Medicaid patients with hepatitis C got Sovaldi. Now, there are a few other brand-name hepatitis C cures on the market, creating some competition. Finally: Insulin After insulin was discovered nearly 100 years ago, the rights to it were transferred to the University of Toronto for $1 so that insulin could be made widely available at a low cost. But insulin prices have continued to creep upward at a rate that's higher than inflation. As a result, some patients have rationed their medicine, skipping doses or cutting them in half. In 2017, a group of patients sued the three major insulin-makers — Sanofi, Eli Lilly and Novo Nordisk — when they noticed that the companies were increasing their prices in lockstep. When Congress and the media took notice, the price hikes mostly stopped, but prices didn't drop. In December, the House passed a bill to lower prescription drug prices.

HAPPY NEW YEAR A Decade Marked By Outrage Over Drug Prices Martin Shkreli, the former CEO of Turing Pharmaceuticals, who was called before Cummings' committee in2016. After hiking the price of an old drug for parasitic infections to $750 a pill from $13.50, Shkreli became the poster boy for pharmaceutical greed that helped define the past decade. Meanwhile, nearly 1 in 4 Americans has trouble affording prescription drugs, according to a Kaiser Family Foundation poll. Of relevance, perhaps to our NA members, Daraprim: An old drug gets a huge new price For decades, Daraprim has been the go-to medicine for treating toxoplasmosis, a parasitic infection especially dangerous for people with compromised immune systems, such as people living with HIV and patients who've undergone organ transplants. The drug was approved by the Food and Drug Administration in 1953, and its patents expired long ago. But there wasn't a generic version available, and there was only one supplier in the United States. Even so, Daraprim cost just $13.50 a pill in early 2015. Then Turing Pharmaceuticals bought the rights to the drug and raised its list price more than 5,000% overnight. Another company called Valeant did the same year when it bought two old heart drugs — Isuprel and Nitropress — that had little competition. Despite public outcry, Daraprim's price hasn't budged. Today, many health insurance companies won't pay for the drug, and it's too expensive for many hospitals to keep in stock, says Armstrong. As a result, she says, doctors have been forced to turn to cheaper alternatives that have more side effects and less proof that they work. Then there is EpiPen, used to counteract allergic reactions. By the time the EpiPen's list price reached $300 per auto-injector in 2016, its manufacturer, Mylan, had made more than a dozen price hikes in just six years. People clamored for a cheaper generic of the product, which injects a dose of epinephrine to counteract allergic reactions. Mylan had a virtual monopoly on it. In the spring of 2016, the FDA had rejected two applications from other firms that wanted to make generic versions. State and federal lawmakers took notice. For years, they had been passing laws that pushed for schools and other public places to have EpiPens on hand. Mylan started offering its own generic at half the price in December 2016 and left the price of its brand-name product where it was. Mylan's new version is called an authorized generic. These are usually introduced to undercut competition from other companies' generics — and eat into some of the competitors' profits. Next consider Sovaldi: a first-of-its-kind hepatitis C drug, priced at $1,000 per pill. To rid a patient of the hepatitis C virus would cost $84,000 per person. State health systems struggled to pay for the treatment, and health insurers denied the drug to all but the sickest patients. An investigation led by Iowa Republican Sen. Chuck Grassley and Oregon Democratic Sen. Ron Wyden found that state Medicaid programs spent more than $1 billion on the drug in 2014, but less than 2.4% of Medicaid patients with hepatitis C got Sovaldi. Now, there are a few other brand-name hepatitis C cures on the market, creating some competition. Finally: Insulin After insulin was discovered nearly 100 years ago, the rights to it were transferred to the University of Toronto for $1 so that insulin could be made widely available at a low cost. But insulin prices have continued to creep upward at a rate that's higher than inflation. As a result, some patients have rationed their medicine, skipping doses or cutting them in half. In 2017, a group of patients sued the three major insulin-makers — Sanofi, Eli Lilly and Novo Nordisk — when they noticed that the companies were increasing their prices in lockstep. When Congress and the media took notice, the price hikes mostly stopped, but prices didn't drop. In December, the House passed a bill to lower prescription drug prices.

WTF Moments: The pharmaceutical and health product industry is by far the biggest spender in terms of lobbying American politicians. Collectively they have spent more than $3.1 billion dollars attempting to influence our elected lawmakers- I wonder what their expense reports look like...9 out of 10 pharmaceutical companies spend more than twice as much on marketing and advertising than research and development. In extreme cases, pharmaceutical companies have raised their prices over 1,000% - In 2015, Valeant Pharmaceuticals raised the price of their drug Daraprim over 5,000%.Halitosis was invented by Listerine. The son of the owner came up with the plan in order to increase direct sales to consumers- they shamed you so hard. Have y’all seen these Listerine ads? They are amazing. According to TIME Magazine- The price of 60 prescription drugs doubled during a recent 12-month span, and prices for 20 of these medications at least quadrupled.Prescription drug spending hit $425 billion in the U.S. last year, before discounting, and the total is expected to reach $640 billion by 2020, according to data from IMS Health Incorporated. Check out our website!Contact us!Support the show (https://www.patreon.com/join/cocktailsandconspiracies?)

In this installment of the Future Grind podcast, host Ryan O'Shea is joined by Michael Laufer. Michael is a mathematician and university professor who has turned his attention to do-it-yourself pharmaceuticals, creating and disseminating open-source plans for low-cost alternatives to expensive medical treatment. He is the chief spokesperson for the Four Thieves Vinegar Collective, and he received a lot of media attention in 2016 after creating a $30 DIY alternative to the EpiPen, which is 10x cheaper than they could be purchased for. His work has been featured by Scientific American, IEEE, Vice, CNN, and more. We discuss the future of healthcare, information as power, and subversion. A word of warning - in this episode, we discuss the production and potential use of home-made pharmaceuticals. Ingesting any of these compounds should be considered extremely dangerous, and things can go wrong. I advise consulting with a trained medical doctor and seeking expert opinions before taking your healthcare into your own hands. Show Notes: https://futuregrind.org Follow along - Twitter - https://twitter.com/Ryan0Shea Instagram - https://www.instagram.com/ryan_0shea/ Facebook - https://www.facebook.com/RyanOSheaOfficial/

Martin Shkreli is often described as the "most hated man in America” for raising the price of a lifesaving drug by 5,000%, earning him the nickname "Pharma bro." Shkreli said his pharmaceutical company raised the price of Daraprim from $13.50 a pill to $750 in order to spend that money on research for an alternative drug, a claim which medical experts widely derided. Now, Shkreli is back in the news and on trial for securities fraud, and while others in his situation might sit quietly and await the verdict, that's not what Shkreli is doing. He can't help himself from making even more attention grabbing headlines.  This week on Money Talking, Host Charlie Herman talks with Renae Merle, a Wall Street and white collar crime reporter for the Washington Post, and Sheelah Kolhatkar, staff writer for the The New Yorker and author of Black Edge: Inside Information, Dirty Money, and the Quest to Bring Down the Most Wanted Man on Wall Street about Shkreli’s case and what it could say about the prosecution of white collar crimes.

Hello, and welcome to The Rob Burgess Show. I am, of course, your host, Rob Burgess. On this, our 13th episode, our guest is Martin Shkreli. Shkreli, a former hedge fund manager and Turing Pharmaceuticals CEO, became internationally infamous in October 2015 when he purchased Daraprim, a drug used to treat toxoplasmosis. There is a good chance you already host toxoplasmosis, especially if you have a cat, but you may never know it. Only children, pregnant mothers and those with weakened immune systems are at risk for developing symptoms. But for those who do, the symptoms can be severe, even fatal. The medication used to treat patients, pyrimethamine, has been available since 1953. Shkreli inspired indignation when he upped the price of the drug by over 5,000 percent from $13.50 per pill to $750. Then, in December 2015, he was arrested by the FBI for securities fraud. He is currently out on bail. On Feb. 4, Shkreli testified before the Committee on Oversight and Government Reform of the U.S. House of Representatives. You'll first hear Shkreli and Republican Utah Rep. Jason Chaffetz and then Republican South Carolina Rep. Trey Gowdy. The album you heard mentioned in another story entirely. Starting in 2008, rap group the Wu-Tang Clan spent five years recording an album only one person, one who couldn't legally profit from until 2103. In May 2015, Shkreli was the winner of an auction for the album, paying $2 million. Here's Wu-Tang Clan leader The RZA being interviewed by Jan. 6, by Bloomberg, who broke the story in December 2015. Later in January, Wu-Tang Clan member Ghostface Killah was asked about Shkreli by TMZ. He responded by calling him a shithead. A few days later, TMZ published a video response from Shkreli, who, stemless wine glass in hand, had three masked men placed behind him. During his Feb. 3 appearance on Power 105.1's “The Breakfast Club,” Shkreli added fuel to the fire. A few days later, Ghostface Killah issued a video response that doubled as a promotion for his CBD oil, Wu Goo. You get the idea. So, here's how I happened to speak with Shkreli. On May 27, Shkreli tweeted the following: “I haven't been called by the Trump camp. I support him vs. Hillary. He should find a VP candidate who is seasoned in politics, an ugly game.” The same day, Colin Daileda of Mashable published an article titled: “America's most hated man endorses its most hated presidential candidate.” On May 28, Shkreli published his phone number, 646-217-2783, on Twitter and asked people who hate him to call him to prove Daileda were wrong. From there, Shkreli and I tweeted back and forth and I dialed his number on a phone without a redial button I knew of for more than 30 minutes. Finally, I got through. I want to thank Josh Sigler and Brandon Chapman of the Sounding Off w/Chap & Sig podcast for the shout outs on their last two episodes. If you're into unfiltered sports talk, I highly suggest checking them out on on Facebook, Twitter, SoundCloud and iTunes. You can help The Rob Burgess Show reach a wider audience by rating, reviewing and subscribing to the podcast on iTunes at tinyurl.com/therobburgessshow. You can also find The Rob Burgess Show on: Stitcher at www.stitcher.com/podcast/the-rob-burgess-show. Google Play Music at tinyurl.com/therobburgessshowgoogleplay. TuneIn at tinyurl.com/therobburgessshowtunein. YouTube at tinyurl.com/therobburgessshowyoutube. You can also subscribe directly to the RSS feed at tinyurl.com/therobburgessshowrss. If you're an Android user visit subscribeonandroid.com/tinyurl.com/therobburgessshowrss You can find more about me by visiting my website, www.thisburgess.com. Follow on Twitter at www.twitter.com/robburgessshow. Like the page on Facebook at facebook.com/therobburgessshow. Follow on SoundCloud at soundcloud.com/the-rob-burgess-show. The email for the show is: therobburgessshow@gmail.com.

Former Turing Pharmaceuticals CEO Martin Schkreli was under the microscope of the govenrment recently due to his poor business practices. But are price controls the answer in the already heavily regulated Pharmaceuticals market? Sincere we are anarchists, you no doubt know our opinion on the matter.Martin Shkreli pleads the Fifth, then tweets about 'imbeciles' in CongressCostly Turing drug gets competitionPharmaceutical offers $1 option to Turing’s $750 AIDS drugDaraprimPharmaceuticals: Economics and RegulationPrice ControlsInterested in learning more about economics, logic, and history? Then sign up for Tom Woods Liberty Classroom.Interested in Bitcoin as an alternative to US Dollars? Use our Coinbase link!If you sign up with our coinbase link and purchase $100 in bitcoin, you will recieve an extra $10 from coinbase.The "Shift" Bitcoin debit card is through coinbase as well.Support the show by entering Amazon through our link HERE!Support the show with Bitcoin HERE!Use this address to add the Logical Anarchy Today show to your podcatcher or subscribe on iTunes!http://shoutengine.com/LogicalAnarchyToday.xml 

In the eighth installment of the OFID podcast, Editor Paul Sax, MD, delves into the headline-making pyrimethamine (Daraprim) saga where Turing Pharmaceuticals increased the price of the recently-acquired toxoplasmosis drug from $13 to $750 a pill. Aaron Kesselheim, MD, JD, MPH, and Joel Gallant, MD, MPH, join the discussion to shed light on what is unique about the generic drug market in the U.S. that makes these dramatic price increases possible and if there will be any resolution.

Topics Discussed: Mobile Podcasting from a Howard Johnson, Boise Idaho, Eating on the Road, Clubbing in Boise, Dave and Buster's Hustle, Flat Land Pressure Systems, Millennial Skill-based Gambling, Let's Do Some Drugs, Snitching Hard, Overstepping Your Bluff, Cheddar Addiction, Martin Shkreli, An Answer to Daraprim, Imprimis Pharmaceuticals, Capitalism Strikes Back, Hojo Experience, Friends and George Lopez, Motel Requirements, You Will Be Killed in a Motel, Summer Salmon Soup and Sushi Season, Idaho Laws, Having Sex in a Car, and Awesome Neighbors.   

LHC tests Rainbow Gravity, Daraprim for a dollar by Ian Woolf, Bright Spark Elizabeth Hine describes how to see genes repaired for Fresh Science sparkler sessions, John August explains the Entropy and the Egg, part 2. Production checked by Charles Willock, Produced and hosted by Ian Woolf Support Diffusion by making a contribution

// Video (Download): // Audio (Download): The post MePod No. 2 // 27 September 2015 // Daraprim and Shkreli appeared first on The Moral Economy.

There is a sinister smell in the air. Corrupt automakers, corrupt politicians, corrupt businesses, and corrupt religions. Choose your poison. 

So theres a guy named Martin Shkreli and he owns a company named Turing Pharmaceuticals. They have a drug called Daraprim used for HIV and he proudly announced this week that he raised the price from $13 a pill to $750 a pill like it was a great thing to do!  Well this pill has a serious group of users that have HIV and the world went into a tizzy cause Martin is proving why being a conservative greedy CEO of company is not cool.  Mark and Bobby discuss this.Then Mark and Producer Bobby go down a unique path as Mark talks about how we are just not happy with the Status quo anymore, yet we don't come up with anything more ingenius than the status quo.  They discuss how Lays potato chips are constantly trying to change the game with new weird flavors and there is nothing wrong with normal old Sour cream and Onion, Cheddar, BBQ and regular potato chips. Where do you stand?  Do you like the 900 varieties or were you fine and life worked well with the orignal 5-7 that already existed.  See where this goes on this episode of the Q. 

The price of Daraprim, a pharmaceutical drug for people with weak immune systems, recently went from $18 to over $750 per pill.

Are we tired of our Government crying wolf so they can keep us under control?

Hillary Clinton, the Democratic front runner in the race for the White House, pledged this week to crack down on the growing cost of prescription drugs and out of pocket medical expenses in the United States after Turing Pharmaceuticals announced that it was hiking the price of the drug Daraprim from $13.50 to $750 a pill. Aimee Keane asks David Crow about the sharp falls in biotech stocks that followed and whether plans such as Mrs Clinton's will end price-gouging. Music: "Starday" by Podington Bear. See acast.com/privacy for privacy and opt-out information.